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ABSTRACT 
 
Amanda Faith Marvelle: The genetics of obesity-related traits and 
lipoproteins in Filipino women 
(Under the direction of Dr. Karen L. Mohlke) 
 
The underlying genetic component of risk factors for cardiovascular disease 
(CVD) is not well understood. Recently, advances in high-throughput genotyping, single 
nucleotide polymorphism (SNP) discovery, and the development of databases such as the 
International Haplotype Map (HapMap) have provided scientists with tools to complete a 
genetic analysis of complex diseases such as CVD.  Research presented in this 
dissertation aims to further understand the genetics of obesity-related traits and 
lipoprotein levels and identify variants that are associated with these traits in a cohort of 
adult women from metro Cebu, Philippines, who participated in the Cebu Longitudinal 
Health and Nutrition Survey (CLHNS). Initially I assess the transferability of tag SNPs 
chosen from HapMap panels to the CLHNS. I show that the Asian HapMap samples are 
an effective resource for studies in the CLHNS.  I then investigate the association 
between 19 candidate variants in 10 genes previously reported to be associated with 
obesity-related traits with similar traits in the CLHNS. We observe evidence for 
association with the A-allele of rs9939609 of FTO and ADRB3 Trp64-allele with obesity 
traits.  I perform a genome-wide association study for HDL-C, triglycerides, LDL-C, and 
total cholesterol.  Among ~2 million SNPs analyzed, we observe evidence of association 
for 11 loci previously described.  We observe suggestive evidence of trait association (P 
< 10-5) for Tankyrase (TNKS) with LDL-C and Collecting-12 (COLEC12) with total 
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cholesterol.  In a separate study, I investigate an HDL-C associated locus, GALNT2, to 
identify functional variants responsible for the association signal.   I identify variants in 
moderate linkage disequilibrium (r2 >.5) with HDL-C associated SNPs, clone regions that 
have suggestive regulatory function into a luciferase reporter vector, and measure 
transcriptional activity in HepG2 cells. The results suggest that a 21 bp deletion, 
rs4849913, and/or rs2144300 may act to increase the transcriptional activity of GALNT2 
or an unknown novel intronic transcript to increase HDL-C. These studies present the 
first genetic study of CVD traits in the CLHNS and a molecular study of a gene that is 
associated with HDL-C.  Together this research provides a solid foundation for one day 
identifying the molecular mechanism underlying complex diseases. 
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 CHAPTER I.  INTRODUCTION 
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 Obesity and unhealthy lipid profiles, along with insulin resistance and high blood 
pressure, increase risk for cardiovascular diseases (CVD) [1].  CVDs are common, 
complex traits with a substantial public health burden.  It is estimated that CVDs are the 
leading cause of morbidity and mortality globally.  Disease prevalence varies with age, 
gender, and population [2]. 
 The genetics of obesity-related traits and lipoproteins are not clearly understood. 
Recently, advances in high throughput genotyping, single nucleotide polymorphism 
(SNP) discovery, and the development of databases such as the International Haplotype 
Map (HapMap) [3] have provided scientists with tools to complete a genetic analysis of 
complex diseases.  This dissertation has taken advantage of these exciting technical 
advances to identify variants that are associated with traits influencing CVD, specifically, 
obesity and lipoprotein levels, in a cohort of women from the Philippines. 
 
CARDIOVASCULAR DISEASES (CVDs) 
Cardiovascular diseases are a group of disorders of the heart and blood vessels.  
The most common reason for these diseases is a build-up of fatty deposits on the walls of 
the blood vessels known as atherosclerosis [2].  Atherosclerotic cardiovascular diseases 
include coronary heart disease, peripheral vascular disease, and stroke. There are several 
risk factors for CVDs.  Environmental risk factors include high fat diet, physical 
inactivity, alcohol and tobacco use.  The effects of these may include increased blood 
pressure, blood glucose, blood lipid levels, and body weight [4]. Other determinants of 
CVDs are poverty and stress [2].  Additionally there is a strong genetic component to 
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CVDs; a recent study found that on average, genetic effects explain 25% of the variance 
for 20 measures of cardiovascular function [5].  
By 2030, an estimated 23.6 million people worldwide will die from CVDs, with 
the largest increase in the number of deaths occurring in the southeast Asia region [6]. 
Increasingly, low and middle income countries are becoming disproportionally affected 
by CVDs, with ~80% of all CVD deaths taking place in these countries.  The populations 
of these countries are more exposed to risk factors leading to CVDs and have less access 
to prevention efforts and effective health care services such as early detection [2].   
 
OBESITY 
Obesity is a worldwide epidemic.  The World Health Organization estimates that 
over 1.6 billion adults worldwide are considered overweight and 400 million of these are 
considered obese.  Once a problem in only high-income countries, obesity prevalence is 
now on the rise in low and middle income countries as well [7]. 
Obesity is a condition in which excess fat has accumulated in the body. Obesity is 
a risk factor for CVD, type 2 diabetes, metabolic syndrome, hypertension, stroke, 
musculoskeletal disorders, and some forms of cancer [8]. Overweight and obesity are 
usually evaluated using body mass index (BMI), defined as weight (in kilograms) divided 
by height (in meters) squared. For both genders and across populations, the World Health 
Organization defines overweight as BMI ≥ 25 kg/m2 and obesity as BMI ≥ 30 [7]. These 
cutoffs provide benchmarks for the relative risk of mortality.  However, in Asian 
subjects, a substantial proportion of individuals with BMI lower than 25 kg/m2 have an 
increased risk of type 2 diabetes and CVD [9].  Therefore, for public health messages 
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lower cutoffs have been proposed for Asian populations (overweight ≥ 23 kg/m2 and 
obese ≥ 25 kg/m2), but not implemented widely.   BMI is correlated with percent body fat 
(r = 0.7-0.8) [10].  Other obesity measures include waist circumference, a measure of 
central adiposity, and skinfold thinknesses, measures of subcutaneous adiposity.  
Many factors influence obesity. The obesity epidemic may reflect the relatively 
new environmental obesogenic factors in society: overall reduced exercise caused by a 
shift from labor intensive jobs to more sedentary work; invention of automated systems 
and motorized vehicles; and increased accessibility and consumption of food with high 
calorie and fat content and low vitamins and nutrients.  Age, poverty, increased number 
of pregnancies to a point, and menopausal status may influence a person’s risk of obesity.   
There is also evidence of a strong genetic component to obesity.  Obesity shows familial 
correlation and aggregation.  Family, twin, and adoption studies have established 
heritability estimates for BMI ranging from 15 to 85 percent [8].  
Worldwide, obesity is a tremendous public health problem, which needs to be 
addressed immediately.  In order to solve this epidemic, it is necessary to understand the 
molecular mechanisms of obesity that will lead to the development medical strategies that 
affect energy balance to help prevent or treat obesity. 
 
LIPOPROTEINS 
Plasma lipoprotein levels are associated with risk of coronary artery disease 
(CAD).  One of the underlying pathologies of CAD is atherosclerosis.  Atherosclerosis 
takes place as low density lipoprotein cholesterol (LDL-C) deposits on the inner lining of 
arteries causing a thickening and hardening of the walls. Eventually the arteries cannot 
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supply blood to the heart or brain leading to myocardial infarction and/or stroke [11].  
There has also been evidence supporting the association of lipoprotein concentration and 
CVD incidence [12,13].  Specifically, higher levels of LDL-C are associated with 
increased CVD with each 1% decrease resulting in a ~1% reduced risk of coronary heart 
disease [14].   Independently, clinical data shows that low levels of high-density 
lipoprotein cholesterol (HDL-C) are associated with increased CAD.  Every 1% increase 
in HDL-C can decrease cardiovascular risk by ~2-3% [15].  Additionally, there is 
evidence that higher levels of triglycerides can lead to an increased risk of CVD [16].    
While diet, exercise, weight, socioeconomic status, age, alcohol consumption, and 
smoking affect levels of lipoproteins, heritability estimates for lipoprotein concentrations 
are as high as 75% [17].  However, the influence of particular genetic variants on 
lipoprotein levels may differ across populations.  For these reasons, there has been 
considerable interest in understanding these genetic factors that contribute to inter-
individual variation. 
 
GENETIC FACTORS IN CARDIOVASCULAR DISEASE  
The identification of genes that contribute to the etiology of CVD and other 
complex diseases and traits has evolved remarkably over the last decade [18].   For 
instance, the identification of variants contributing to the inter-individual variation of 
lipoprotein levels initially proved difficult.  Mutations in genes such as LDLR, APOB, 
ABC1, and APOA1 were identified in families with severe hypercholesterolemia, 
defective apoB100, familial combined hyperlidemia, and extremely low HDL-C [19].  
Nonetheless, mutations causing these extreme phenotypes are relatively rare.  Most of the 
6 
phenotypic variation in the general population may be due to multiple common genetic 
variants all with a small contribution. In the 1980’s and 90’s numerous loci were 
identified in sib-pair and family linkage studies [20-24] and in association studies of 
variation in known lipoprotein metabolism candidate genes (apopliporproteins, lipolytic 
enzymes, receptors, and transporters) [25].  However, replication was inconsistent 
between studies [25], but the majority of these studies were statistically underpowered.  
More recently, significantly more statistically powered genome wide association (GWA) 
studies have consistently replicated genes originally identified through other approaches 
such as CETP, LIPC, ABCA1, LIPG, APOE-APOC1-APOC4-APOC2 cluster, APOB, 
LDLR, APOA5-APOA4-APOC3-APOA1 cluster, GCKR, and LPL and have identified loci 
not previously implicated in lipid metabolism [26]. 
As of 2005, the Human Obesity Gene Map reported 426 statistically significant 
associations between an obesity-related phenotype and a DNA variant in 127 candidate 
genes.  Of these genes, 22 were supported by positive replication in at least five studies 
[27].  However, additional reports exist for these loci that are inconsistent with 
preliminary data. 
In the spring of 2003, the Human Genome Project mapped more than a million 
SNPs, locations in the genome where a single nucleotide (A, T, C, or G) varies between 
individuals [28]. By observing which common SNPs are inherited alongside diseases, 
researchers have been able to locate genes and regions of the genome that increase an 
individual’s risk to disease.  These studies are known as GWA studies and have been 
made possible by the continuing advances in SNP discovery, genotyping technologies, 
and statistical tools to analyze large data sets.  This technique allows researchers to study 
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the variation across the entire genome rather than focusing on a single gene or prior 
hypothesis.  These studies have been remarkably successful [29]. 
Recent GWA studies in populations of primarily European descent have identified 
many loci that are associated with blood lipoprotein levels [30-42] and obesity [43-51].  
Many variants are being identified in genes and regions of the genome that have not been 
previously selected as candidates for obesity and lipoproteins. Additionally, many loci 
are being identified as associated with multiple traits and diseases.  Despite the large 
number of loci identified in these studies, the associated SNPs only explain a small 
proportion of the heritability within these traits, suggesting that many genetic factors 
remain to be identified.  There are still other types of genetic variants not yet evaluated 
including but not limited to copy number variants and less common SNPs. 
Furthermore, examining understudied ethnic groups may identify additional genes 
that are associated with disease.  Asian populations are undergoing socio-economic 
development and lifestyle changes, which are resulting in an increase of CVD burden 
[52].  The environmental differences between European and Asian populations may 
modify the effect of genetic variants on obesity and lipoprotein levels.  Additionally, 
because of the potential differences in genetic architecture (patterns of linkage 
disequilibrium and allele frequencies) between Asian and European individuals, genetic 
variants identified in populations of European descent may differ in Asian populations.  
For example, variants in KCNQ1 were first identified to be associated with type 2 
diabetes in an Asian population [53,54], but it was not until later that the association was 
verified in Caucasians because of ancestry-related differences in the allele frequencies 
increasing the power to detect an association in an Asian population compared to a 
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European population (frequency 5% versus 40%) [55].  This example demonstrates the 
value of using diverse populations to identify complex-trait associations. 
 
THE CEBU LONGITUDINAL HEALTH AND NUTRITION SURVEY (CLHNS)  
The Cebu Longitudinal Health and Nutrition Survey  (CLHNS) is an ongoing 
population study that began in 1983 (www.cpc.unc.edu/projects/cebu).  The CLHNS is a 
birth cohort of Filipino women and their children spanning one year (May 1, 1983 to 
April 30, 1984), providing a representative sample of births over all seasons.  This 
dissertation focuses on the mothers of this cohort.  Baseline interviews were conducted 
on 3,327 women during their 6th to 7th month of pregnancy.  Surveys took place 
immediately after birth, then every two months for 24 months.  Follow-up surveys were 
conducted in 1991, 1994-5, 1998-99, 2002, 2005, and 2007.  The 2005 survey collected 
blood for DNA and biomarkers, clinical, and phenotypic data on 1,889 un-related 
mothers.  
 The CLHNS data was collected during in-home surveys using structured 
questionnaires by qualified and trained interviewers.  All surveys collected 
socioeconomic, demographic, community, environmental, diet, physical activity, and 
anthropometric data.  Height, weight, mid-upper arm circumference, and triceps skinfold 
thickness were measured in all surveys; waist and hip circumferences were measured in 
the 1998 to 2005 surveys, and suprailiac skinfold thickness was measured in the 2005 
survey.  Data on menopause status was collected beginning in 1991.  Complete 
reproductive history including the total number of pregnancies, months pregnant, and 
months lactating was updated at each survey.  Plasma was collected in 2005 from which 
9 
biomarkers such as HDL-C, triglycerides, LDL-C, and total cholesterol have been 
measured.  
 The CLHNS was initially designed to investigate the determinants and 
consequences of infant feeding and maternal health; however, the wealth of data 
collected by this study over the past 22 years has allowed the focus of the work to 
expand.  Most recently, researchers have been focusing on CVD risk factors including 
weight, fat patterning, lipoprotein levels, hypertension, and diabetes.  However, I am the 
first to look at the genetic associations with obesity-related traits and lipoprotein levels 
within the women of CLHNS. 
 
THE INTERNATIONAL HAPLOTYPE MAP: LINKAGE DISEQUILIBIRUM 
AND TAG SNPs 
For efficient genotyping, GWA studies make use of patterns of linkage 
disequilibrium (LD) between genetic polymorphisms [46,47].  SNPs located near each 
other tend to be correlated.  While a region may contain many SNPs, often only a few are 
needed to uniquely identify the common haplotypes across this region.  When alleles of 
two SNPs are inherited together more often than expected based on the product of their 
allele frequencies, the SNPs are said to be in LD with each other.  One measure of LD is 
the squared correlation coefficient, r2.  For example, when two SNPs are perfectly 
redundant, r2=1; when they are completely independent, r2=0.  LD patterns reflect the 
ancestry of a population and vary considerably throughout the genome [48-50].  The 
International Haplotype Map Consortium has studied and cataloged DNA sequence 
variation and characterized the patterns of LD across the genome [3], allowing correlated 
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SNPs to be excluded from genotyping, but considered in analysis.  The first phases of 
HapMap were made up of four panels of dense haplotype maps for individuals 
characterized as Han Chinese from Beijing, China (CHB), Japanese from Tokyo, Japan 
(JPT), Caucasians from Utah, USA with northern and western European ancestry (CEU), 
and Yoruban of Ibadan, Nigeria (YRI) and reported more than 3.1 million SNPs across 
the genome with an average SNP density of 1 SNP/ 760bp [3].  Most recently in 2009, 
HapMap phase III was released and contains genotype data from 1,115 individuals from 
11 populations (http://hapmap.ncbi.nlm.nih.gov/).  
Measures of LD, gene density, and haplotype blocks vary across the genome 
[51,52], and the HapMap ENCyclopedia Of DNA Elements (ENCODE) reference 
regions represent a range of these and other genomic characteristics [53].  These regions 
were re-sequenced in 48 unrelated individuals (8 CHB, 8 JPT, 16 CEU, and 16 YRI) for 
SNP discovery and reflect the actual density of SNPs in the genome more accurately than 
other regions in HapMap [54]. 
The HapMap is an important resource for choosing tag SNPs in disease 
association and population studies [3]. Through extensive SNP discovery and 
simulations, de Bakker et al. 2006 [55] showed that the power to detect disequilibrium-
based association is only modestly compromised when an appropriate selection of tag 
SNPs are chosen from HapMap samples and applied to other case-control samples.  For 
populations similar to those genotyped in the HapMap project, HapMap data may be used 
to impute or directly predict genotypes of non-tag SNPs for analysis in association 
studies [56,57].  Utilizing the patterns of haplotype variation has been very useful in 
inferring missing genotype in silico using imputation to deduce genotypes of more SNPs 
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across the genome.  However, prior to this dissertation very little genetic data was 
available for Filipinos, and data was unavailable to assess the effectiveness of using the 
existing HapMap data to guide SNP selection and interpretation for samples from the 
CLHNS samples. 
 
IDENTIFYING FUNCTIONAL VARIANTS WITHIN LOCI IMPLICATED IN 
DISEASE BY GWA STUDIES  
In the past three years, GWA studies have successfully identified dozens of loci 
confirmed to be strongly associated with CVD traits [17,20].  These results are only the 
beginning of understanding how each locus may contribute to disease.  A GWA study 
may report only the most associated SNP, but in some cases hundreds of variants may 
account for the association signal.  Additionally, for some loci, the associated variants 
span a large number of genes or are located in regions of the genome where there are no 
known protein-coding genes.  One of the next steps towards understanding the molecular 
mechanisms of obesity-related traits and lipoproteins is to identify the exact underlying 
variants and genes contributing to an association signal.  
 There are many potential molecular mechanisms for a functional SNP.  In the 
simplest scenario, a SNP allele can cause a nonsense, frameshift, or missense substitution 
altering a key amino acid residue or altogether destroying the function or activity of a 
protein [58-60].  However, many of the recent association signals identified in GWA 
studies are entirely located in non-coding sequence, suggesting that non-coding variation 
plays an important role in common disease.  Non-coding SNPs may influence biological 
processes by reducing transcription factor binding affinity; modifying RNA splicing or 
12 
polyadenylation; or influencing mRNA stability, microRNAs, or microRNA target sites.  
One loci identified in recent GWA studies, GALNT2, contains at least eight SNPs within 
the non-coding sequence of intron one that are associated with HDL-C (all P < 1 x 10-7) 
[29,33].  
Most DNA is wound around a histone core, forming nucleosomes.  When DNA is 
in this state, it is inaccessible to transcription factors, RNA polymerase, or trans-
regulatory factors.  DNA segments that are actively regulating transcription are 
characterized by the depletion of nucleosomes from the chromatin [61].  Several 
experimental approaches can help identify open chromatin.  These include DNase I 
hypersensitivity (DHS) [62], formaldehyde-assisted identification of regulatory elements 
(FAIRE) [63], markers of histone modification [64], and chromatin immunoprecipitation 
(ChIP) with regulatory proteins [65].  Open chromatin can differ between tissues, and 
data from these techniques is becoming available for many medically relevant cell types.  
By combining predictions of regulatory variants with SNP data, we may be able to 
predict and experimentally test functional regulatory variants that contribute to CVD 
traits such as enhancers or promoters. 
 
RESEARCH PRESENTED IN THIS DISSERTATION   
As described in the subsequent chapters, the overall goals of this dissertation are as 
follows:   
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Chapter II. 
Assess the similarity of genetic variants in the CLHNS samples with the variants in 
four HapMap samples.  Using 627 SNPs from 10 HapMap ENCODE reference regions, 
I employ allele frequency estimates, pairwise LD (r2), and haplotype frequency estimates 
as measures of similarity to compare four HapMap populations to the individuals of the 
CLHNS.  Furthermore, I study the efficiency of tag SNPs selected from two HapMap 
East Asian panels for capturing genetic variation in CLHNS samples. 
Hypothesis:  The CLHNS samples are more genetically similar to the Asian HapMap 
samples, CHB and JPT, because they are geographically related.  
 
Chapter III. 
Examine whether selected SNPs reported to be associated with obesity-related traits 
in other populations are also associated with similar traits in the CLHNS samples.   
I perform tests of association in the CLHNS using SNPs selected from the literature 
based on previous evidence of association with an obesity-phenotype in other 
populations.  I test association with BMI, waist circumference, and percent body fat for 
all SNPs.  For SNPs with evidence for association with at least one trait, I further test for 
association with additional phenotypes: baseline BMI (measured in 1983-84), weight, fat 
mass, Triceps skinfold thickness, suprailiac skinfold thickness, arm fat area, arm muscle 
area, and height.  I also examine whether these SNPs modify the effect of established 
environmental risk factors of diet and physical activity level by performing tests of 
interaction between genotype and total caloric intake, estimated percent dietary fat and 
carbohydrates, and activity level.  Additionally I perform a longitudinal analysis 
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incorporating all available BMI measurements (for the up to eight measurements) 
spanning 22 years. 
Hypothesis:  Some but not all of the previously reported SNPs are associated with 
obesity-phenotypes in the CLHNS samples reflecting environmental and genetic 
differences between the CLHNS cohort and previously studied populations, statistical 
power, and false positive results in the literature. 
 
Chapter IV 
Test evidence of association between SNPs and plasma lipoprotein levels in the 
CLHNS samples in a GWA study.  Using the Affymetrix Genome-Wide Human SNP 
Array 5.0, I genotype 1,889 CLHNS women on ~500K SNPs and perform association 
analysis on 2.3 million genotyped or imputed SNPs for HDL-C, LDL-C, triglycerides, 
and total cholesterol.  I perform conditional analyses to evaluate whether any additional 
SNPs were independently associated with an outcome after accounting for the most 
associated SNP at the association signal. 
Hypothesis: Some of the previously reported associated SNPs show evidence of 
association with lipoprotein levels in the CLHNS samples and additional putative novel 
loci are identified to be associated in the CLHNS population. 
 
Chapter V. 
Evaluate allele-specific effects on transcriptional regulation for HDL-C associated 
SNPs located in intron 1 of the GALNT2 gene.  After developing a more 
comprehensive list of potential functional variants in the GALNT2 association region, I 
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prioritize the variants based on sequence annotation and maps of open chromatin from 
hepatocytes and test high priority variants for allele-specific effects on promoter and 
enhancer activity.   
Hypothesis: A functional SNP(s) within the region of association may act as an enhancer 
or promoter.   
 
Chapter VI.  
Synthesize the findings of the research chapters and describe the future of genetics 
of obesity-related traits and lipoproteins.  Together these findings represent important 
contributions to the field of human genetics and will serve as building blocks for future 
studies.  
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ABSTRACT 
Patterns of linkage disequilibrium (LD) act as the framework for designing 
efficient association studies; these patterns are being studied and catalogued by The 
International HapMap Project.  The current study assessed the transferability of tag SNPs 
chosen from HapMap panels to a cohort of 80 individuals from metro Cebu, Philippines, 
who participated in the Cebu Longitudinal Health and Nutrition Survey (CLHNS).  The 
analyses focused on 627 single nucleotide polymorphisms (SNPs) in the central 40 kb 
within each of the 10 HapMap ENCODE regions.  The similarity between the genetic 
variants in Cebu Filipino samples and HapMap panels was examined using allele 
frequency estimates, measures of pairwise LD, and haplotype frequency estimates.  For 
these measures, strong correlations were observed between the Cebu Filipino samples 
and the Asian panels from HapMap, with the strongest correlations observed with the 
Han Chinese from Beijing (CHB) panel.  Tag SNPs selected using the HapMap CHB 
panel were particularly effective at representing the genetic variation in Cebu Filipino 
samples.  These results suggest that the HapMap data will be an effective resource for 
future studies in Cebu Filipino samples.
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INTRODUCTION 
Genetic association studies make use of patterns of linkage disequilibrium (LD) 
between genetic polymorphisms for efficient genotyping [1,2].  LD patterns reflect the 
ancestry of a population and vary considerably throughout the genome [3-5].  The 
International HapMap Consortium is studying and cataloguing DNA sequence variation 
and characterizing these patterns of LD across the genome [6], allowing correlated single 
nucleotide polymorphisms (SNPs) to be excluded from genotyping but considered in 
analysis.  The HapMap is made up of four panels of dense haplotype maps for individuals 
characterized as Han Chinese from Beijing, China (CHB), Japanese from Tokyo, Japan 
(JPT), Caucasians from Utah, USA with northern and western European ancestry (CEU), 
and Yoruban of Ibadan, Nigeria (YRI). 
The HapMap is an important resource for choosing tag SNPs in disease 
association and population studies [6].  However, worldwide population variation is not 
completely characterized, and an essential question is whether tag SNPs chosen using 
HapMap panels will adequately capture patterns of genetic variation in other populations 
[7-17].  Furthermore, for populations similar to those genotyped in the HapMap project, 
HapMap data may be used to directly predict genotypes of non-tag SNPs for analysis in 
association studies [18,19].  Previous studies observed that the HapMap CHB and JPT 
panels have very similar patterns of LD and could act as a proxy for other geographically 
related populations [20-25].  However, data is currently unavailable to assess the 
effectiveness of using the existing HapMap data to guide SNP selection and interpretation 
for samples from the Cebu Longitudinal Health and Nutrition Survey (CLHNS) cohort 
from metro Cebu in the central Philippines [26,27].  This study assesses the advantages of 
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having HapMap data from two related Asian panels to evaluate whether the combined 
CHB and JPT panels would more effectively capture genetic variability in Cebu Filipinos 
than the CHB or JPT panels alone.  In addition, this study develops the most efficient 
criteria for selecting tag SNPs from the HapMap panels for future genetic association 
studies in Cebu Filipino samples. 
To address these issues, SNPs from within the 10 HapMap ENCyclopedia Of 
DNA Elements (ENCODE) reference regions were used [28].  These regions were re-
squenced in 48 unrelated individuals (8 CHB, 8 JPT, 16 CEU, and 16 YRI) for SNP 
discovery and reflect the density of SNPs in the genome more accurately than other 
regions in HapMap.  The SNP density in these ENCODE regions is higher than the 
remainder of HapMap [6].  The similarity of the HapMap samples to 80 Cebu Filipino 
samples was assessed, using allele frequency estimates, pairwise LD (r2), and haplotype 
frequency estimates as measures of similarity.  Furthermore, the efficiency of using tag 
SNPs selected from the HapMap Asian panels for capturing genetic variation in Cebu 
Filipino samples was studied. 
 
MATERIALS AND METHODS 
Samples 
Eighty unrelated Cebu Filipino individuals were randomly selected from a cohort 
of healthy women from the CLHNS (www.cpc.unc.edu/projects/cebu).  Informed consent 
was obtained from all individuals and the study protocol was approved by the University 
of North Carolina Institutional Review Board for the Protection of Human Subjects. 
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Genomic DNA was isolated from peripheral blood lymphocytes using automated 
and manual DNA extraction methods (Puregene, Gentra) by the University of North 
Carolina, Chapel Hill BioSpecimen Processing Facility.  Centre d’Etude du 
Polymorphisme Humain (CEPH) DNA samples were obtained from Coriell (Camden, 
NJ, USA). 
HapMap genotype data was obtained from the HapMap database 
(www.hapmap.org) for all available unrelated individuals, including 45 CHB, 44 JPT, 60 
CEU parents of trios, and 60 YRI parents of trios.  For some analysis, the CHB and JPT 
samples were combined (indicated as CHB+JPT) [6]. 
 
SNP selection and genotyping  
To represent the overall complexity of the genome, the central 40 kb region from 
within each of the ten 500 kb ENCODE regions that have been used for SNP discovery 
and dense SNP genotyping was chosen for this study (Table 2.1).  SNPs were selected if 
they were polymorphic (minor allele frequency, MAF, >0) in the HapMap CHB, JPT, or 
CEU panels. 
Of the 883 SNPs that met these criteria, 215 were eliminated based on Illumina 
design score (calculated December 2005).  One SNP identified by re-sequencing region 
ENr213 in Cebu Filipino samples (see below) was included, resulting in a total of 669 
SNPs that were genotyped in the Cebu Filipino samples.  SNP genotyping was performed 
at the Mammalian Genotyping Core at the University of North Carolina, Chapel Hill 
using the Illumina GoldenGate (Illumina Inc., San Diego, USA) genotyping assay [29].  
Of the 669 SNPs attempted, 36 SNPs were excluded based on poorly-defined clusters 
29 
(n=28), genotyping completeness <90% (n=3), or inconsistency with Hardy-Weinberg 
Equilibrium (P < .001) (n=5).  Six additional SNPs were excluded because of two or 
more genotype discrepancies between six CEPH DNA samples and equivalent HapMap 
CEU genotypes.  SNPs were also evaluated for two or more genotyping discrepancies 
between seven duplicate samples, however no SNPs needed to be dropped based on this 
criterion.  The genotyping success rate of the final 627 SNPs was 99.9% and the 
discrepancy rate was .02%.  Of these 627 SNPs, 501 (80%) were polymorphic (MAF > 0) 
in Cebu Filipino samples. The average marker spacing of these 501 polymorphic SNPs 
was 1 SNP/798 bp. 
 
Statistical analysis 
Tests for consistency of genotype distributions with expected Hardy-Weinberg 
equilibrium proportions were calculated using standard Pearson’s χ2 statistics.  Only 
markers with a MAF ≥ .05 in HapMap panels were analyzed in Cebu Filipino samples.  
SNPs were matched for the reference allele between all HapMap panels and Cebu 
Filipino samples.  Fisher’s exact tests were used to test for allele frequency differences 
between pairs of samples.  Pair-wise LD (r2) values were calculated using Haploview [30; 
http://www.broad.mit.edu/mpg/haploview] for adjacent pairs and all pairs of SNPs in 
each region.  Haplotype blocks were defined in Haploview for each HapMap panel based 
on the default block definition [31].  Identical blocks from each HapMap panel were 
defined in the Cebu Filipino samples for comparison.  Using Haploview, haplotype 
frequencies were estimated in each haplotype block for every population.  Haplotypes 
with a frequency > .01 were evaluated in the HapMap panels.  Haplotypes not observed 
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in the Cebu Filipino samples were assigned a frequency of zero.  Spearman’s correlation 
coefficients were calculated for all comparisons between Cebu Filipino samples and 
HapMap panels. 
In order to evaluate the efficiency of HapMap to choose tag SNPs for Cebu 
Filipino samples, tag SNPs from HapMap panels were selected using Tagger in pairwise 
tagging mode with other settings at default values [32; 
http://www.broad.mit.edu/mpg/tagger/].  Several r2 thresholds were used to assess the 
performance of selecting tag SNPs using the HapMap panels: .80, .85, .90, and .95.  If a 
Cebu Filipino SNP exhibited pairwise r2 ≥ .80 with at least one tag SNP (selected from 
the Asian HapMap panels), then the SNP was defined as captured in the Cebu Filipino 
sample.  Percent coverage for a region is defined as the number of captured SNPs in the 
Cebu Filipino samples divided by the total number of SNPs (with estimated MAF ≥ .05).  
Finally, for each Cebu Filipino SNP, the maximum r2 estimate obtained over all r2 
estimates between that SNP and a tag SNP in the region was identified.  For a region, 
mean maximum r2 was defined as the average value of the maximum r2 values obtained 
over all Cebu Filipino SNPs in the region. 
 
Re-sequencing 
Twenty-four randomly chosen Cebu Filipino samples were re-sequenced in the 
central 800 nucleotide (nt) region within each of the 40 kb ENCODE regions.  Primers 
were selected using Primer3 software [33; 
http://www.genome.wi.mit.edu/genome_software/other/primer3.html] and sequences 
were compared using Sequencher 4.2.2 (Gene Codes Corporation, Ann Arbor, MI, USA).   
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Sequencing was performed at the University of North Carolina, Chapel Hill automated 
DNA sequencing facility on an ABI Prism 3730 (Applied Biosystems, Foster City, CA, 
USA) using the Big Dye Terminator Kit. 
 
RESULTS 
 To determine the extent of similarity between 80 Cebu Filipino samples and 
HapMap samples, genotype data for 627 SNPs located within the 10 HapMap ENCODE 
regions was used (Table 2.1). 
 
Allele frequencies 
Allele frequency estimates were compared using SNPs with MAF ≥ .05 in the 
corresponding HapMap panel.  A total of 399 SNPs were evaluated when examining 
CHB, 391 SNPs for JPT, 396 SNPs for CHB+JPT, 431 SNPs for CEU, and 391 SNPs for 
YRI.  The Spearman’s correlation coefficients for allele frequency estimates between the 
Cebu Filipino samples and the HapMap panels were .96, .92, .95, .82, and .65 for CHB, 
JPT, CHB+JPT, CEU, and YRI, respectively (Figure 2.1).  For comparison, the 
Spearman’s correlation coefficient for allele frequency estimates between CHB and JPT 
samples was .95 for 384 SNPs with MAF ≥ .05 in both panels.  The percent of SNPs with 
significantly different allele frequencies (Fisher’s exact p-value < .01) was 5.7% for 
CHB, 15.6% for JPT, 11.6% for CHB+JPT, 57.7% for CEU, and 60.1% for YRI.  
Although larger sample sizes should provide greater power to detect statistically 
significant differences, the 89 CHB+JPT samples showed fewer significant differences 
with the Cebu Filipino samples than the smaller JPT, CEU, or YRI groups.  The allele 
frequency comparison was repeated using HapMap SNPs with MAF > 0 and slightly 
32 
higher Spearman’s correlations were obtained with analogous patterns of similarity (data 
not shown). 
Based on the substantially greater similarity in allele frequencies between Cebu 
Filipino samples and Asian HapMap panels compared to CEU or YRI panels, subsequent 
analyses were performed using only the HapMap CHB, JPT and CHB+JPT panels. 
 
Linkage disequilibrium  
Pairwise r2 for adjacent pairs and all pairs of SNPs within each HapMap 
ENCODE region in the Asian HapMap samples and Cebu Filipino samples were 
estimated to evaluate the extent of LD in each population.  Only SNPs with MAF ≥ .05 in 
the corresponding HapMap sample were included in comparisons.  Analysis was 
performed for 375, 368, and 373 adjacent pairs of SNPs and 9350, 8912, and 9157 total 
pairs of SNPs for CHB, JPT, and CHB+JPT, respectively.  The Spearman’s correlation 
coefficients of the r2 estimates for adjacent pairs of SNPs between the Cebu Filipino and 
Asian HapMap samples were .90 for each of CHB, JPT, and CHB+JPT.  The Spearman’s 
correlation coefficients of the r2 estimates for all pairs were .88 for CHB, .87 for JPT, and 
.89 for CHB+JPT (Table 2.2).  The absolute difference between r2 estimates of adjacent 
SNP pairs was calculated.  For CHB 51%, 73%, and 85% of the SNPs had absolute 
differences between r2 estimates of ≤ .05, ≤ .10, and ≤ .15; for JPT 48%, 67%, and 80% 
of the SNPs had absolute differences between r2 estimates of ≤ .05, ≤ .10, and ≤ .15; and 
for CHB+JPT 50%, 69%, and 83% of the SNPs had absolute differences between r2 
estimates of ≤ .05, ≤ .10, and ≤ .15. 
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When each of the ten regions was analyzed separately, LD differed both among 
regions and populations.  Region ENr232 varied the most between HapMap panels; 
Spearman’s correlation coefficients of the r2 estimates, for all pairs of SNPs, between the 
Cebu Filipino and Asian HapMap samples were .85 for CHB, .63 for JPT, and .77 for 
CHB+JPT.  This region, however, did not differ from the other regions in allele 
frequency estimates, haplotype frequency estimates (below), and tag SNP analyses 
(below).  The pairwise r2 analysis was repeated using all HapMap SNPs with MAF > 0 
and obtained slightly higher Spearman’s correlations but analogous patterns of similarity 
(data not shown).  To confirm that Cebu Filipino sample size did not impact results, the 
analysis was repeated with three random sets of 45 Cebu Filipino samples.  The sets of 45 
were compared to CHB and JPT panels, and similar results were observed to the total set 
of 80 Cebu Filipino samples (data not shown).  On average across all regions, Cebu 
Filipino samples show highly similar patterns of LD compared to all Asian panels, with 
slightly more similarity observed with CHB+JPT panels and slightly less observed with 
JPT panels. 
 
Haplotype frequencies 
Haplotype frequencies for the Asian HapMap panels and Cebu Filipino samples 
were estimated for haplotypes comprised of SNPs with MAF ≥ .05 in the HapMap panel.  
Haplotype blocks were defined using the default block definition used in Haploview [31].  
Within the 10 regions, the average number of blocks per region was 3.6, 3.6, and 3.3 for 
CHB, JPT and CHB+JPT respectively.  The blocks ranged in size from 2 to 65 SNPs 
with an average of 9.7, 10.9, and 9.1 SNPs per block for CHB, JPT, and CHB+JPT.  One-
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hundred and seventy-eight, 151, and 141 haplotypes were identified with frequency 
estimates > .01 in CHB, JPT, and CHB+JPT, respectively.  The Spearman’s correlation 
coefficient of haplotype frequency estimates between Cebu Filipino and Asian HapMap 
samples was .95 for CHB, .88 for JPT, and .92 for CHB+JPT (Figure 2.2).  Most 
haplotypes with an estimated frequency > 0 in the Asian samples were also observed 
(with estimated frequency > 0) in Cebu Filipino samples, demonstrating a high degree of 
haplotype conservation across the populations. Of the observed haplotypes with 
estimated frequency ≥ .05 in CHB, JPT, and CHB+JPT, only 2.5% (3 of 119), 2.8% (3 of 
107), and 1.8% (2 of 112), respectively, were not observed in Cebu Filipino samples. In 
addition, of the observed haplotypes with estimated frequency > .01 in CHB, JPT, and 
CHB+JPT, 23% (41 of 178), 24% (36 of 151), and 11% (16 of 141), respectively, were 
not observed in Cebu Filipino samples.  The greater representation of Cebu Filipino 
haplotypes in CHB+JPT samples is likely attributed to the larger sample size.  Overall, 
the haplotype frequency differences were modest between Cebu Filipino samples and the 
Asian HapMap panels, with CHB showing the most similarity and JPT showing the least 
similarity. 
 
Transferability of tag SNPs 
To measure the efficiency of using the HapMap panels for tag SNP selection in 
the Cebu Filipino population, Tagger was used to select tag SNPs from the CHB, JPT, 
and CHB+JPT panels for SNPs with MAF ≥ .05.  Tag SNP coverage was tested at four r2 
thresholds for selection in the HapMap panels, and the tag SNPs chosen in HapMap 
panels were applied to SNPs with MAF ≥ .05 in Cebu Filipino samples. 
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Overall, at each r2 selection threshold using the CHB, JPT, and CHB+JPT panels 
the percentages of SNPs captured (with a mean r2 ≥ .80) in the Cebu Filipino samples 
were very similar.  Using any of the three panels for SNP selection, the lowest r2 
selection threshold of .80 captured at least 82-83% of Cebu Filipino SNPs (MAF ≥ .05) 
across all ten regions (Table 2.3).  To obtain this percent coverage 121, 118, and 125 tag 
SNPs from CHB, JPT, and CHB+JPT, respectively, would need to be genotyped.  As 
expected, increasing the r2 threshold for selecting tag SNPs in the Asian HapMap samples 
increased both the number of tag SNPs that needed to be genotyped and the proportion of 
Cebu Filipino SNPs captured by these tag SNPs.  However, the percent coverage of each 
region varied substantially.  At the r2 selection threshold of .80, the percent coverage 
ranged over the 10 regions from 54% to 96%, 59% to 96%, and 52% to 94% using CHB, 
JPT, and CHB+JPT tag SNPs, respectively.  This variability between regions was still 
observed at a r2 selection threshold of .95, the highest r2 threshold studied.  In addition, at 
each r2 selection threshold, the mean maximum r2 of all Cebu Filipino SNPs (MAF ≥ .05) 
was similar between CHB, JPT, and CHB+JPT.  Among all SNPs, for the r2 selection 
threshold of .80, a mean maximum r2 of .88 was observed using CHB, JPT, and 
CHB+JPT tag SNPs.  As expected, the mean maximum r2 increased at each increase of 
the r2 selection threshold.  Little variability was observed between regions (data not 
shown). 
At each r2 selection threshold, the SNPs in the Cebu Filipino samples that were 
not captured by a tag SNP selected in the HapMap panels were evaluated.  The 
percentage of SNPs not captured and the mean maximum r2 for each SNP were calculated 
(Table 2.3).  Consistent with the sensitivity of tag SNP selection to allele frequency [34], 
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many of the SNPs not captured were rare (MAF < .10).  These rare SNPs had low mean 
maximum r2, and were not captured using higher r2 selection thresholds.  Common SNPs 
(MAF ≥ .10) that were not captured at an r2 of at least .80 were captured with at least a 
mean maximum r2 of .65, .64, and .66 using CHB, JPT, and CHB+JPT tag SNPs, 
respectively.  As the r2 selection threshold increased, more of these Cebu Filipino 
common SNPs were captured with an r2 of at least .80. 
 
Re-sequencing 
To assess the frequency of population-specific novel SNPs and to further evaluate 
the genetic structure in Cebu Filipinos, 24 Cebu Filipino individuals were re-sequenced 
in an 800 nt region within each of the 10 HapMap ENCODE regions used previously for 
HapMap re-sequencing [28].  Approximately 184 kb on at least one DNA strand were re-
sequenced.  Only one novel SNP was detected that was not present in HapMap (data 
release 21, July 06) or dbSNP (build 126); the SNP was located in region ENr213 
(ss69374772) and had a MAF of .05 in 80 Cebu Filipino individuals.  Within Cebu 
Filipino samples, this SNP exhibited a maximum r2 of .228 with 4 other SNPs in the 40 
kb region. 
 
DISCUSSION 
The extent of similarity between Cebu Filipino samples and the previously 
evaluated HapMap samples were examined using measures of allele frequency estimates, 
pairwise r2 estimates, and haplotype frequency estimates.  Consistent with population 
migration, mitochondrial DNA, and Y haplotype patterns [35], CEU and YRI samples 
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were much less similar to Cebu Filipino samples with respect to allele frequency than 
CHB, JPT, or CHB+JPT samples.  All of the analyses showed high similarity between 
Asian HapMap samples and Cebu Filipino samples. 
Because the CHB and JPT samples have similar allele frequencies, these data sets 
are often combined for analyses [6].  The existence of these two Asian HapMap panels 
allowed for evaluating the choice of using CHB, JPT, or the larger combined CHB+JPT 
panel as a resource for choosing haplotype tagging SNPs for Cebu Filipino samples.  
Among these three panels, JPT samples were the least correlated with Cebu Filipino 
samples with respect to allele frequency estimates, pairwise r2 estimates, and haplotype 
frequency estimates. Cebu Filipino and CHB allele frequency estimates were more 
closely correlated than CHB and JPT allele frequency estimates.  Both CHB and 
CHB+JPT panels were very similar to Cebu Filipino samples, and it is not clear which 
panel would act most efficiently as a proxy for the Cebu Filipino samples.  The larger 
CHB+JPT sample size would be expected to decrease the variability in the allele and 
haplotype frequency estimates; the added JPT samples could decrease accuracy.  Indeed, 
estimated Cebu Filipino allele and haplotype frequencies were slightly more correlated 
with CHB than CHB+JPT, but Cebu Filipino pairwise r2 estimates were slightly more 
similar to CHB+JPT than CHB. 
A practical use of HapMap is to select tag SNPs for regional or genome-wide 
association studies [6].  Evaluation was performed on the transferability of HapMap tag 
SNPs chosen using the data from CHB, JPT, and CHB+JPT panels at several r2 selection 
thresholds, with respect to capturing the genetic variability in samples from Cebu, 
Philippines.  Using these criteria, at an r2 selection threshold of .80, the HapMap-based 
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tag SNPs capture 82-83% of the Cebu Filipino SNPs.  A majority of the most common 
SNPs (MAF ≥ .10) in the Cebu Filipino sample that are not captured by the tag SNPs at 
an r2 of at least .80 are captured with an r2 of at least .60.  Using higher r2 thresholds for 
tag SNP selection in the HapMap samples results in capturing more SNPs in the Cebu 
Filipino sample, but with the added cost of genotyping more tag SNPs.  Increasing the r2 
threshold failed to capture substantially more rare SNPs, most of which exhibited low 
pairwise LD with other SNPs. 
Previously, de Bakker et al. [22] showed through extensive SNP discovery and 
simulations that power to detect disequilibrium-based association is only modestly 
compromised when an appropriate selection of tag SNPs are chosen from HapMap 
samples and applied to other case-control samples.  Large scale SNP discovery and 
power simulations were beyond the scope of this study.  However, based on the findings 
from de Bakker et al. [22] and the current findings that tag SNPs selected using the Asian 
HapMap adequately captured common Cebu Filipino SNPs, the average loss in power to 
detect common casual alleles should be small. 
Re-sequencing and genotyping was preformed in the 10 HapMap ENCODE 
regions that were re-sequenced for SNP discovery and are considered to be a “gold 
standard” because of the high density of SNP coverage [28].  Only one SNP (estimated 
MAF = .05) was detected in the Cebu Filipino samples that was not observed in dbSNP 
or HapMap, suggesting that alleles ascertained from the HapMap ENCODE regions were 
representative of the common variation in Cebu Filipinos and that additional re-
sequencing of these regions would not be required to detect common SNPs in Cebu 
Filipino samples.  While future SNP selection in genome regions that have not been re-
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sequenced will be based on less complete SNP identification, the Asian HapMap panels 
will likely either include or tag most of the common SNPs present in Cebu Filipino 
samples. 
Measures of LD, gene density, and haplotype blocks vary across the genome 
[10,36], and the HapMap ENCODE regions analyzed represent a range of these and other 
characteristics [36], suggesting that our results may apply, on average, across the 
genome.  The strong correlations observed between Cebu Filipino samples and HapMap 
Asian panels are broadly consistent with other assessments of tagging transferability 
outside the HapMap ENCODE regions [7-17,24]. 
Our results are consistent with previous studies that compared the Asian HapMap 
panels to other Eastern Asian samples.  Studies that examined many populations 
worldwide found Asian and Oceania populations to be most similar to the Asian HapMap 
panel tested [13,23].  Two studies have investigated the tagging transferability between 
the HapMap CHB, JPT, and CHB+JPT with sample sets from Thailand and from Korea 
[24,25].  A combination of tag SNPs from CHB+JPT best captured the LD structure of 
the Thais, while SNP selection based on JPT was most transferable to the Korean 
samples.  In comparison, our results suggest that CHB samples and the combined 
CHB+JPT samples are most similar to Cebu Filipino samples.  Although our results do 
not necessarily reflect the patterns of genetic variability across the Philippines, our 
findings will be useful for the future design and analysis of genetic studies in the Cebu 
Filipino population. 
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Table 2.1: Number of SNPs successfully genotyped by population and region 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Total number of SNPs (MAF > 0, MAF ≥ .05) 
Region 40 kb Positions  NCBI Build 35 (hg17) 
Cebu 
Filipino CHB JPT CHB+JPT CEU YRI 
ENr112 Chr2:51800356..51840356 76 (52,46) 75 (46,45) 75 (46,45) 75 (47,45) 76 (73,46) 75 (58,51) 
ENr131 Chr2:234503825..234543825 96 (91,83) 81 (75,73) 81 (77,72) 81 (77,72) 93 (86,77) 85 (74,70) 
ENr113 Chr4:118834259..118874259 99 (84,80) 92 (77,74) 92 (77,71) 92 (77,71) 96 (91,78) 92 (78,64) 
ENm010 Chr7:26960761..27000761 40 (27,25) 39 (33,24) 39 (30,23) 39 (36,24) 38 (29,23) 36 (23,20) 
ENm013 Chr7:89658340..89698340 64 (42,35) 60 (41,38) 60 (41,37) 60 (42,38) 63 (58,43) 61 (41,34) 
ENm014 Chr7:125901178..125941178 53 (41,37) 49 (39,34) 49 (38,33) 49 (41,34) 53 (46,39) 49 (30,30) 
ENr321 Chr8:119112221..119152221 57 (47,36) 55 (47,42) 55 (45,36) 55 (48,42) 56 (43,36) 53 (41,41) 
ENr232 Chr9:128994856..129034856 34 (30,29) 33 (30,28) 33 (29,29) 33 (30,29) 34 (24,21) 33 (25,21) 
ENr123 Chr12:38856477..38896477 52 (40,27) 50 (36,24) 50 (39,23) 50 (42,23) 50 (42,29) 47 (34,26) 
ENr213 Chr18:23949232..23989232 56 (47,30) 55 (25,17) 55 (42,22) 55 (45,18) 54 (50,39) 55 (42,34) 
Sum across all regions 627 (501,428) 589 (449,399) 589 (464,391) 589 (485,396) 616 (542,431) 616 (542,431) 
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Table 2.2: Spearman's correlation coefficients of all pairwise r2 estimates between 
HapMap Asian panels and Cebu Filipino samples 
 
Region CHB JPT CHB+JPT 
ENr112 .886 .896 .897 
ENr131 .707 .710 .761 
ENr113 .931 .913 .937 
ENm010 .857 .874 .886 
ENm013 .897 .950 .929 
ENm014 .894 .832 .830 
ENr321 .845 .812 .844 
ENr232 .848 .630 .768 
ENr123 .668 .705 .681 
ENr213 .755 .766 .701 
Average .877 .870 .888 
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Table 2.3: Coverage of the Cebu Filipino samples by tag SNPs selected from Asian 
HapMap panels 
 
r2 
threshold 
for tag 
SNP 
selection 
Number 
of tag 
SNPs 
selected 
Captured* SNPs  Un-captured* SNPs,     MAF 
< .10  
Un-captured* SNPs,     
MAF ≥ .10 
Percent# Mean 
maximum r2 $  Percent
#
 
Mean 
maximum r2 $  Percent
#
 
Mean 
maximum r2 $ 
CHB          
.80 121 82.4 .877  4.0 .142  13.6 .649 
.85 134 85.7 .878  5.4 .113  10.1 .679 
.90 152 91.5 .917  4.0 .141  4.7 .702 
.95 179 92.0 .923  4.0 .140  4.0 .680 
          
JPT          
.80 118 83.1 .877  4.5 .143  12.4 .642 
.85 125 83.1 .876  7.5 .352  9.4 .632 
.90 137 90.6 .896  4.5 .147  4.9 .610 
.95 159 92.5 .916  4.2 .123  3.3 .518 
          
CHB+
JPT          
.80 125 82.4 .882  4.2 .160  13.4 .656 
.85 132 88.5 .900  4.2 .162  7.3 .651 
.90 144 89.0 .906  4.2 .166  6.8 .626 
.95 170 93.0 .923  4.0 .140  3.1 .589 
 
Only SNPs with an allele frequency ≥ .05 in the HapMap panel and the Cebu Filipino samples were 
analyzed.   
*A SNP is considered captured it if exhibited a pairwise r2 estimate ≥ .80 with at least one tag SNP.   
#Percent coverage is defined as the number of SNPs in the Cebu Filipino samples captured by a tag SNP 
divided by the total number of SNPs.   
$Mean maximum r2 is the average of the maximum pairwise r2 estimates obtained between each SNP 
within a region and a tag SNP. 
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Figure 2.1: Comparison of allele frequency estimates between Cebu Filipino samples 
and HapMap samples for SNPs with MAF ≥ .05 in the HapMap sample.  Open 
symbols indicate SNPs with significantly different allele frequencies at a Fisher’s exact P 
value < .01 
 
.
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Figure 2.2: Comparison of haplotype frequency estimates between Cebu Filipino 
samples and Asian HapMap samples for SNPs with MAF ≥ .05 in the HapMap 
sample and haplotype frequency estimates > .01 in the HapMap sample 
 
.
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ABSTRACT 
OBJECTIVE: The underlying genetic component of obesity-related traits is not 
well understood, and there is limited evidence to support genetic association shared 
across multiple studies, populations, and environmental contexts.  The present study 
investigated the association between candidate variants and obesity-related traits in a 
sample of 1,886 adult Filipino women from the Cebu Longitudinal Health and Nutrition 
Survey (CLHNS) cohort.  RESEARCH DESIGN AND METHODS: We selected and 
genotyped 19 single nucleotide polymorphisms in 10 genes (ADRB2, ADRB3, FTO, 
GNB3, INSIG2, LEPR, PPARG, TNF, UCP2, and UCP3) that had been previously 
reported to be associated with an obesity-related quantitative trait.  RESULTS: We 
observed evidence for association of the A allele of rs9939609 (FTO intron 1) with 
increased BMI (P = .0072 before multiple test correction), baseline BMI (P = .0015), 
longitudinal BMI based on eight surveys from 1983 to 2005 (P = .000029), waist 
circumference (P = .0094), and weight (P = .021).  The increase in average BMI was 
approximately .4 for each additional A allele.  We also observed association of the 
ADRB3 Trp64Arg variant with BMI, waist circumference, percent body fat, weight, fat 
mass, arm fat area, and arm muscle area (P < .05), although the direction of effect is 
inconsistent with the majority of previous reports.  CONCLUSIONS: Our study confirms 
that FTO is a common obesity susceptibility gene in Filipinos, with an effect size similar 
to that seen in samples of European origin. 
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INTRODUCTION 
Obesity is a worldwide epidemic, affecting individuals across all age groups, 
socioeconomic classes, and ethnicities. In addition, obesity is a risk factor for 
cardiovascular disease, type 2 diabetes, metabolic syndrome, hypertension, stroke, and 
some forms of cancer [1].  This complex and heterogeneous disorder arises from 
interactions between environment, behavior, and genetics.  
Although many association studies have attempted to identify genetic variants that 
influence obesity, replication has been infrequent.  As of 2005, 22 candidate genes 
contained a variant reported to be significantly associated (P < .05) with an obesity-
related trait in at least five studies [2].  However, additional reports for these genes are 
inconsistent. 
Recently, genome-wide association (GWA) studies have identified variants in 
additional genes.  Single nucleotide polymorphism (SNP) rs7566605, near insulin-
induced gene 2 (INSIG2), found to be associated with increased body mass index (BMI) 
[3], has not been consistently replicated [4-7].  Several variants in the fat mass and 
obesity associated (FTO) gene identified through two independent GWA studies [8,9] 
and a third study [10] were associated with BMI and risk of being overweight in children 
and adults in cohorts of Europeans, European-Americans, and Hispanic-Americans, but 
not in African Americans.  Significant FTO association was also observed for hip 
circumference, waist circumference, and subcutaneous fat mass assessed using skinfolds 
[8,9].  Two studies observed FTO association with percentage of fat mass and dual 
energy X-ray absorptiometry derived fat mass in children [8,10].  FTO variants have the 
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most consistent replication across multiple populations to date, suggesting this locus is a 
likely risk factor for obesity. 
In the current study, we examined 19 SNPs previously reported to be associated 
with obesity-related phenotypes for association with BMI, waist circumference, and 
percent body fat in 1,886 Filipino women from the Cebu Longitudinal Health and 
Nutrition Survey (CLHNS).  In addition, for SNPs with initial evidence of association, 
we performed analysis with additional phenotypes and tested for interaction with diet and 
physical activity. 
 
MATERIALS AND METHODS 
Study subjects and traits  
We evaluated 1,886 unrelated healthy Cebu Filipino female participants in the 
ongoing CLHNS [11], mothers of a 1983 to 1984 birth cohort.  Trained field staff 
conducted in-home interviews and collected measurements and comprehensive 
environmental data (www.cpc.unc.edu/projects/cebu). We used non-pregnant data 
collected from surveys in 1983-84 (“baseline” = four months post-partum), 1984-85 (one 
year post-partum), 1985-86 (two years post-partum), 1991, 1994, 1998, 2002, and 2005.  
For 2005 cross-sectional traits, outcome and covariate measures from the 2002 survey 
were substituted for 16 women who were pregnant or missing data in 2005. 
All outcome and covariate measures, except baseline BMI, were taken from the 
2005 survey.  Triceps and suprailiac skinfold thicknesses (TSF and SiSF) represent the 
mean of three consecutive Harpenden caliper measurements.  Cross-sectional arm muscle 
area (AMA) and arm fat area (AFA) were calculated using mid arm circumference and 
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triceps skinfold thickness. Body density was calculated using the Durnin-Womersley sum 
of skinfold equation based on TSF and SiSF for adult women from 16 to 68 years of age 
[12], and percent body fat was derived from body density using the Siri equation [13].  
Fat mass was calculated as the product of percent body fat and weight.  Height was 
calculated as an average of eight measures across surveys from 1983-84 to 2005.  Dietary 
intake was assessed by 24-hour dietary recall, with nutrient composition calculated from 
the Philippines Food Composition Table [14].  Physical activity level was categorized 
based on time use data, with a focus on occupational activity: each job was classified 
according to its metabolic equivalents based on field studies in Filipino women [15] and 
the Compendium of Physical Activity [16]. 
 Informed consent was obtained from all individuals, and the study protocol was 
approved by the University of North Carolina Institutional Review Board for the 
Protection of Human Subjects.  Genomic DNA was isolated from peripheral blood 
lymphocytes (Puregene, Gentra) by the University of North Carolina, Chapel Hill 
BioSpecimen Processing Facility. 
 
SNP selection and genotyping methods 
We reviewed genes that exhibited nine or more reports of association with an 
obesity phenotype as summarized by the 2004 obesity gene map [2].  SNPs within these 
genes with more than three positive reports of association and a minor allele frequency > 
.01 in the CHB HapMap samples were subsequently chosen to be genotyped.  Variants in 
FTO and INSIG2 identified through GWA studies were also genotyped [3,8].   
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Genotyping was performed using TaqMan allelic discrimination (Applied 
Biosystems, Foster City, CA).  The genotype success rate for all SNPs was >98% and the 
discrepancy rate among duplicate samples was .1%. 
 
Statistical analysis 
Tests for consistency of genotype distributions with expected Hardy-Weinberg 
equilibrium proportions were calculated using Pearson’s χ2 statistic; only rs3856806 was 
inconsistent (P = .02).  All SNPs were tested for association with three primary 
phenotypes: 2005 measures of BMI, waist circumference, and percent body fat.  Analysis 
of covariance (ANCOVA) models were used to test for association between genotype and 
the continuously distributed outcomes.  Logistic regression models were used for 
dichotomous outcomes. Only SNPs with evidence for association with at least one trait 
were tested for association with additional phenotypes. We also examined whether these 
SNPs modify the effect of established environmental risk factors of diet and physical 
activity level by performing tests of interaction between genotype and total caloric intake, 
estimated percent dietary fat and carbohydrates, and activity level.  We also performed a 
longitudinal analysis incorporating all available BMI measurements for the up to eight 
measurements spanning 22 years using general linear mixed models.   
Models were adjusted for age, household assets, natural log of income, number of 
total pregnancies as a categorical variable (1-4, 5-10, >10), and menopausal status; 
baseline BMI is not adjusted for menopausal status. Continuously distributed traits were 
transformed to satisfy the model assumption of normally distributed residuals, 
conditional on the covariates.  The additive mode of inheritance assumption was used 
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unless fewer than 15 rare homozygotes existed; the dominant mode of inheritance 
assumption for the minor allele was used for SNPs rs4994, rs8179183, rs1801282, and 
rs1800629.  The rs9939609 SNP in FTO was also analyzed under both the additive and 
dominant models for comparison to previous reports.  Because of low linkage 
disequilibrium (r2 < .5) between pairs of SNPs, Bonferroni adjustment was used to 
account for multiple SNPs.  
 
RESULTS 
Nineteen SNPs described previously to be associated with obesity-related 
phenotypes were tested for evidence of association with 2005 measures of BMI, waist 
circumference, and percent body fat in 1,886 unrelated non-pregnant Filipino women in 
the CLHNS cohort (Table 3.1).  Two SNPs were statistically significantly associated (P < 
.01) with at least one trait before adjustment for multiple SNPs (Table 3.2). The A-allele 
of SNP rs9939609 (FTO intron 1) was associated with increased BMI (P = .0072) and 
waist circumference (P = .0094).  The TT homozygote (Trp64) of SNP rs4994 (ADRB3 
Trp64Arg) was associated with increased BMI (P = .00069) and waist circumference (P = 
.0013).  After Bonferroni correction for multiple SNPs, only rs4994 in ADRB3 remained 
significant (P < .002), however, only the FTO association was consistent in magnitude 
and direction of effect with previous reports [8-10]. 
To further investigate the rs9939609 and rs4994 SNPs, we analyzed additional 
obesity-related phenotypes of baseline BMI (measured in 1983-84), weight, fat mass, 
SiSF, TSF, AFA, AMA, and height (Table 3.3).  For FTO variant rs9939609, significant 
evidence of association was observed with baseline BMI (P = .0015) and weight (P = 
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.021).  Marginally significant p-values (.05 < P < .10) were observed for fat mass (P = 
.055) and AMA (P = .084), with direction of estimated effects consistent with those seen 
for BMI and weight.  For the ADRB3 variant rs4994, significant evidence of association 
was observed for weight (P = .0011), fat mass (P = .0036), AFA (P = .016), and AMA (P 
= .0008), and marginally significant p-values were observed for TSF (P = .068), with the 
direction of estimated effects consistent with those observed for BMI and weight.  Unlike 
the FTO variant, no evidence for association was observed with baseline BMI (P = .55). 
We analyzed risk of being either overweight and obese (BMI ≥ 25 kg/m2) or 
obese (BMI ≥ 30 kg/m2) [17] both in 1983-84 and in 2005 (Table 3.4).  Using these 
criteria, 793 and 178 women had a BMI ≥ 25 kg/m2 or BMI ≥ 30 kg/m2, respectively, in 
2005, and 94 women had a BMI ≥ 25 kg/m2 in 1983-84.  The A-allele of rs9939609 was 
associated with increased risk of being overweight in 2005 (P = .0034) and in 1983-84 (P 
= .023).  The TT homozygote of rs4994 was associated with increased risk of being 
overweight in 2005 (P = .0077) and 1983-84 (P = .044) and obese in 2005 (P = .023). 
There was no evidence for interaction between genotype and either the 2005 
dietary intake (total calories, estimated percent diet from fat, and estimated percent diet 
from carbohydrates) or physical activity measures (P > .05 for all tests). 
A longitudinal analysis of BMI included an average of 7.3 (range 3 to 8) 
measurements per individual spanning 22 years. The global P value for the test of 
association with rs9939609 was .000029 (additive model, Fig. 3.1A) and .016 for rs4994 
(Fig. 3.1B).  The direction of the genotype-specific least-squares means at each time 
point was consistent with the cross-sectional analysis. The test of rs9939609 genotype-
by-time interaction was significant (P = .047), with a slight increasing effect of genotype 
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over time.  For rs4994, the test of genotype-by-time interaction was highly significant (P 
= .0065), with evidence for an increasing effect of genotype over time. 
 
DISCUSSION 
We evaluated 19 SNPs in a sample of adult Filipino women from the CLHNS 
cohort, confirmed the association of the A-allele of FTO variant rs9939609 with BMI and 
waist circumference, and observed evidence for an association with the TT homozygote 
of ADRB3 rs4994 with BMI, waist circumference, and percent body fat.  While only 
rs4994 reached significance after Bonferroni correction, the direction of effect was not 
consistent with the majority of previous reports [8-10].  The failure to replicate many of 
the SNP associations that have been reported previously may reflect environmental and 
genetic differences between the CLHNS cohort and previously studied populations, 
limited statistical power, and/or false positive results in the literature. 
We also observed evidence for association between the Trp64 allele of rs4994 and 
increased weight, percent fat mass, AFA, AMA, and longitudinal BMI.  However, we did 
not observe evidence for association with baseline BMI (measured at a time when few 
women were overweight).  In contrast to our study, two meta-analyses with over 35 
subgroups each, one in Japanese and one in multiple populations, reported that Arg64 
carriers exhibited significantly higher mean BMI than Trp64 homozygotes [18,19].  The 
ADRB3 receptor is more abundant and active in visceral adipose tissue than subcutaneous 
adipose [20]; however, we observed evidence for association between rs4994 and 
measures of both visceral and subcutaneous fat.  The observation of significant 
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associations, but with opposite alleles associated with increased trait values across 
studies, suggests that these results should be interpreted with caution.  
The FTO rs9939609 A-allele was also significantly associated with several 
obesity-related traits including longitudinal BMI, which reflects a relatively constant 
genotype effect over 22 years and strengthens the evidence that this locus influences BMI 
in this population.  We observed an effect even at younger ages among women with 
smaller BMIs, consistent with previous reports in children [8,10].  We observed evidence 
for an association with waist circumference, but not an association with skinfold 
thicknesses, a measurement of subcutaneous adiposity, consistent with variation in FTO 
influencing central adiposity to a greater extent than subcutaneous fat. 
The minor allele frequency (MAF) of the rs9939609 variant is .18 in the CLHNS 
samples, less common than observed in European populations (MAF = .45-.48).  
Recently, Li et al. [21] suggested that the lack of association of rs9939609 with obesity in 
a population of Han Chinese may be due to a decreased allele frequency.  This is not 
consistent with our findings of significant association. 
In summary, our results corroborate previous reports that a SNP within the first 
intron of FTO is associated with BMI.  The FTO SNPs have the most consistent prior 
evidence for association with obesity-related traits reported to date, and our study 
replicates this evidence, both in direction and approximate magnitude, in a Filipino 
population, suggesting FTO may be important in many genetic backgrounds. 
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Table 3.1: Characteristics of 1,886 women in the Cebu Longitudinal Health and 
Nutrition Survey 
  Mean (SD) 
BMI (kg/m2) 24.3 (4.4) 
Waist circumference (cm) 81.1 (10.8) 
Percent body fat 36.6 (5.4) 
BMI (baseline 1983-84) (kg/m2) 20.6 (2.4) 
Arm fat area (mm2) 9.6 (1.5) 
Arm fat mass (mm2) 60.0 (17.6) 
Fat mass (kg) 20.6 (6.3) 
Suprailiac skinfold (mm) 28.8 (10.1) 
Triceps skinfold (mm) 23.8 (8.0) 
Weight (kg) 55.1 (10.9) 
Average height (cm) 150.4 (4.9) 
Age (years) 48.4 (6.1) 
Total number of pregnancies 6.5 (3.0) 
Menopausal status (yes/no) 1162/724 
All traits are measured from 2005 survey except where indicated.  For women who were 
pregnant or missing data in 2005, measures from the 2002 survey were substituted.  Baseline 
BMI was collected from postpartum surveys in 1983-1984 (see methods).
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Table 3.2: Results of SNPs assessed for association in the CLHNS 
cohort with BMI, waist circumference, and percent body fat 
Trait SNP rs# Gene SNP Alias 
Minor/ 
MAF 
Minor Allele 
Homozygotes Heterozygotes 
Major Allele 
Homozygotes 
p-
value Major 
Allele Mean (95% CI) n Mean (95% CI) n Mean (95% CI) n  
BMI rs1042711 ADRB2 Cys19Arg C/T .147 
24.3  
(23.0, 25.6) 40 23.8 (23.4, 24.2) 437 24.1 (23.8, 24.4) 1287 .38 
(kg/m2) rs1042713 ADRB2 Gly16Arg G/A .463 
23.9  
(23.5, 24.3) 389 24.1 (23.8, 24.4) 857 24.0 (23.6, 24.4) 518 .67 
 rs1042714 ADRB2 Gln27Glu G/C .146 
24.3  
(23.0, 25.6) 39 23.8 (23.4, 24.2) 440 24.1 (23.8, 24.4) 1291 .41 
 rs4994* ADRB3 Trp64Arg C/T .085 
22.3  
(19.9, 24.7) 11 23.3 (22.8, 23.9) 278 24.2 (23.9, 24.4) 1476 .0011 
 rs9939609 FTO Intron 1 A/T .175 
24.7  
(23.7, 25.7) 64 24.5 (24.1, 24.8) 508 23.9 (23.6, 24.1) 1249 .0072 
 rs6489738 GNB3 Ser275Ser C/T .377 
24.0  
(23.4, 24.5) 241 24.0 (23.7, 24.3) 828 24.1 (23.7, 24.4) 667 .68 
 rs7566605 INSIG2 -10kb C/G C/G .450 
24.2  
(23.7, 24.6) 355 24.0 (23.7, 24.3) 872 23.9 (23.5, 24.3) 532 .29 
 rs1137100 LEPR Lys109Arg A/G .224 24.5 (23.7, 25.3) 96 23.6 (23.3, 24.0) 598 24.2 (23.9, 24.5) 1073 .058 
 rs1137101 LEPR Gln223Arg A/G .143 24.5 (23.1, 25.8) 36 23.8 (23.4, 24.2) 426 24.1 (23.8, 24.4) 1280 .34 
 rs3790419 LEPR Ser343Ser G/A .108 24.9 (23.1, 26.7) 20 23.8 (23.4, 24.3) 336 24.1 (23.8, 24.4) 1389 .39 
 rs8179183* LEPR Lys656Asn C/G .029 22.9 (17.2, 28.6) 2 23.7 (22.9, 24.6) 96 24.0 (23.8, 24.3) 1624 .49 
 rs1805096 LEPR Pro1019Pro C/T .147 24.6 (23.3, 25.8) 44 23.7 (23.3, 24.1) 432 24.1 (23.9, 24.4) 1287 .14 
 rs1801282* PPARG Pro12Ala G/C .048 21.0 (16.9, 25.0) 4 24.2 (23.6, 24.9) 167 24.1 (23.8, 24.3) 1657 .74 
 rs3856806 PPARG 1431 C/T T/C .219 23.4 (22.6, 24.3) 101 23.9 (23.5, 24.3) 570 24.1 (23.9, 24.4) 1091 .053 
 rs1799724 TNF -857 C/T T/C .127 23.4 (21.8, 24.9) 26 24.2 (23.7, 24.6) 396 24.0 (23.7, 24.3) 1341 .81 
 rs1800629* TNF -308 G/A A/G .040 26.1 (20.4, 31.8) 2 24.2 (23.5, 24.9) 137 24.0 (23.8, 24.3) 1612 .74 
 rs659366 UCP2 -866 G/A A/G .297 24.2 (23.6, 24.9) 163 23.9 (23.5, 24.2) 718 24.2 (23.8, 24.5) 875 .5 
 rs660339 UCP2 Ala55Val T/C .299 24.1 (23.5, 24.8) 167 23.8 (23.5, 24.2) 721 24.2 (23.9, 24.5) 876 .32 
 rs1800849 UCP3 -55 C/T T/C .226 24.1 (23.3, 25.0) 91 24.1 (23.7, 24.4) 608 24.0 (23.7, 24.3) 1050 .96 
                
Waist  rs1042711 ADRB2 Cys19Arg C/T .147 80.7 (77.5, 83.9) 40 79.7 (78.7, 80.8) 437 80.7 (80.1, 81.4) 1286 .20 
circ. rs1042713 ADRB2 Gly16Arg G/A .463 80.2 (79.1, 81.3) 389 80.5 (79.7, 81.3) 856 80.7 (79.7, 81.7) 518 .42 
(cm) rs1042714 ADRB2 Gln27Glu G/C .146 80.6 (77.3, 83.9) 39 79.8 (78.8, 80.9) 440 80.7 (80.1, 81.4) 1290 .22 
 rs4994* ADRB3 Trp64Arg C/T .085 75.2 (69.1, 81.5) 11 79.1 (77.8, 80.3) 278 80.8 (80.1, 81.4) 1475 .0026 
 rs9939609 FTO Intron 1 A/T .174 81.1 (78.5, 83.7) 64 81.7 (80.7, 82.7) 507 80.1 (79.4, 80.7) 1249 .0094 
 rs6489738 GNB3 Ser275Ser C/T .377 80.3 (79.0, 81.7) 241 80.7 (79.9, 81.5) 827 80.5 (79.6, 81.4) 667 .87 
 rs7566605 INSIG2 -10kb C/G C/G .450 80.6 (79.5, 81.8) 355 80.5 (79.7, 81.3) 871 80.4 (79.5, 81.4) 532 .83 
 rs1137100 LEPR Lys109Arg A/G .224 81.3 (79.2, 83.4) 96 79.7 (78.8, 80.6) 598 80.9 (80.1, 81.6) 1072 .20 
 rs1137101 LEPR Gln223Arg A/G .143 81.3 (77.9, 84.7) 36 80.2 (79.1, 81.2) 426 80.5 (79.8, 81.2) 1279 .73 
 rs3790419 LEPR Ser343Ser G/A .108 80.8 (76.3, 85.4) 20 80.0 (78.8, 81.2) 336 80.7 (80.0, 81.3) 1388 .36 
 rs8179183* LEPR Lys656Asn C/G .029 84.6 (70.2, 99.0) 2 80.1 (78.0, 82.2) 96 80.5 (79.8, 81.1) 1623 .83 
 rs1805096 LEPR Pro1019Pro C/T .148 81.1 (78.0, 84.2) 44 80.2 (79.1, 81.2) 432 80.6 (79.9, 81.3) 1286 .53 
 rs1801282* PPARG Pro12Ala G/C .048 73.0 (62.8, 83.1) 4 80.7 (79.1, 82.3) 167 80.6 (80.0, 81.3) 1656 .92 
 rs3856806 PPARG 1431 C/T T/C .219 78.8 (76.7, 80.8) 101 80.3 (79.3, 81.2) 570 80.8 (80.1, 81.5) 1090 .059 
 rs1799724 TNF -857 C/T T/C .127 77.3 (73.3, 81.3) 26 80.9 (79.8, 82.0) 396 80.4 (79.8, 81.1) 1340 .88 
 rs1800629* TNF -308 G/A A/G .040 85.0 (70.6, 99.4) 2 81.5 (79.7, 83.3) 137 80.5 (79.8, 81.1) 1611 .28 
 rs659366 UCP2 -866 G/A A/G .297 80.7 (79.1, 82.3) 163 80.5 (79.6, 81.3) 718 80.6 (79.8, 81.3) 874 .99 
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 rs660339 UCP2 Ala55Val T/C .299 80.5 (78.9, 82.1) 167 80.4 (79.5, 81.2) 721 80.6 (79.8, 81.4) 875 .68 
 rs1800849 UCP3 -55 C/T T/C .226 80.6 (78.4, 82.8) 91 80.8 (79.9, 81.7) 608 80.4 (79.6, 81.1) 1049 .58 
           
Percent  rs1042711 ADRB2 Cys19Arg C/T .146 35.9 (34.4, 37.5) 40 36.0 (35.5, 36.5) 434 36.4 (36.1, 36.7) 1285 .17 
body fat rs1042713 ADRB2 Gly16Arg G/A .463 35.8 (35.2, 36.3) 388 36.5 (36.1, 36.8) 854 36.3 (35.8, 36.8) 517 .19 
 rs1042714 ADRB2 Gln27Glu G/C .146 35.9 (34.4, 37.5) 39 36.0 (35.5, 36.5) 437 36.4 (36.1, 36.7) 1289 .18 
 rs4994* ADRB3 Trp64Arg C/T .085 35.6 (32.7, 38.5) 11 35.7 (35.1, 36.3) 278 36.4 (36.1, 36.7) 1471 .050 
 rs9939609 FTO Intron 1 A/T .175 36.8 (35.6, 38.0) 64 36.4 (35.9, 36.9) 508  36.3 (36.0, 36.6) 1249 .43 
 rs6489738 GNB3 Ser275Ser C/T .378 36.3 (35.6, 36.9) 241 36.2 (35.8, 36.6) 826 36.4 (36.0, 36.8) 664 .64 
 rs7566605 INSIG2 -10kb C/G C/G .450 36.3 (35.8, 36.9) 354 36.3 (35.9, 36.7) 870 36.2 (35.7, 36.7) 530 .60 
 rs1137100 LEPR Lys109Arg A/G .224 36.7 (35.7, 37.7) 96 35.9 (35.5, 36.4) 597 36.4 (36.1, 36.8) 1069 .49 
 rs1137101 LEPR Gln223Arg A/G .143 36.5 (34.9, 38.1) 36 36.2 (35.7, 36.8) 425 36.3 (35.9, 36.6) 1276 .92 
 rs3790419 LEPR Ser343Ser G/A .108 37.4 (35.2, 39.5) 20 35.9 (35.3, 36.5) 335 36.4 (36.1, 36.7) 1385 .54 
 rs8179183* LEPR Lys656Asn C/G .029 36.9 (30.0, 43.8) 2 36.0 (35.0, 37.0) 96 36.3 (35.9, 36.6) 1619 .68 
 rs1805096 LEPR Pro1019Pro C/T .147 36.6 (35.2, 38.1) 44 36.1 (35.6, 36.6) 430 36.4 (36.0, 36.7) 1284 .62 
 rs1801282* PPARG Pro12Ala G/C .048 35.4 (30.6, 40.3) 4 36.7 (35.9, 37.4) 167 36.3 (36.0, 36.6) 1648 .55 
 rs3856806 PPARG 1431 C/T T/C .220 36.0 (35.1, 37.0) 101 36.3 (35.9, 36.8) 570 36.3 (35.9, 36.6) 1086 .98 
 rs1799724 TNF -857 C/T T/C .127 36.2 (34.3, 38.1) 26 36.2 (35.7, 36.8) 395 36.3 (36.0, 36.6) 1337 .80 
 rs1800629* TNF -308 G/A A/G .04 38.3 (31.4, 45.2) 2 36.1 (35.3, 37.0) 137 36.3 (36.0, 36.6) 1608 .62 
 rs659366 UCP2 -866 G/A A/G .298 36.4 (35.7, 37.2) 163 36.2 (35.8, 36.6) 716 36.3 (36.0, 36.7) 872 .92 
 rs660339 UCP2 Ala55Val T/C .299 36.3 (35.6, 37.1) 167 36.1 (35.7, 36.5) 719 36.4 (36.0, 36.8) 873 .59 
  rs1800849 UCP3 -55 C/T T/C .226 36.1 (35.1, 37.1) 91 36.2 (35.8, 36.7) 607 36.3 (36.0, 36.7) 1046 .60 
Untransformed means are reported.  Models were adjusted for age, 
assets, number of pregnancies, income, and menopausal status.  *All 
tests were performed under the additive model except for SNPs with 
fewer than 15 minor allele homozygotes, in which case a dominant 
mode of inheritance assumption for the minor allele was used.
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Table 3.3: Association of FTO and ADRB3 SNPs with obesity-related traits 
 FTO rs9939609 Additive Dominant  ADRB3 rs4994 Dominant 
  TT TA AA p-value p-value  TT TC/CC p-value 
BMI (kg/m2) 23.9 (23.6, 24.1) 24.5 (24.1, 24.8) 24.7 (23.7, 25.7) .0072 .0080  24.2 (23.9, 24.4) 23.3 (22.8, 23.8) .0011 
Waist circumference 
(cm) 80.1 (79.4, 80.7) 81.7 (80.7, 82.7) 81.1 (78.5, 83.7) .0094 .0040  80.8 (80.1, 81.4) 78.9 (77.7, 80.2) .0026 
Percent body fat 36.3 (36.0, 36.6) 36.4 (35.9, 36.9) 36.8 (35.6, 38.0) .43 .47  36.4 (36.1, 36.7) 35.7 (35.1, 36.3) .0499 
Baseline BMI (kg/m2) 20.5(20.3, 20.6) 20.9 (20.7, 21.1) 21.0 (20.4, 21.6) .0015 .0013  20.6 (20.5, 20.8) 20.5 (20.3, 20.8) .55 
Weight (kg) 54.2 (53.5, 54.8) 55.3 (54.3, 56.2) 55.9 (53.4, 58.4) .021 .024  54.8 (54.1, 55.4) 52.6 (51.4, 53.9) .0011 
Fat mass (kg) 20.1 (19.7, 20.5) 20.6 (20.1, 21.2) 20.9 (19.5, 22.3) .055 .06  20.4 (20.0, 20.7) 19.3 (18.6, 20.0) .0036 
Suprailiac skinfold 
thickness (mm) 28.3 (27.6, 28.9) 28.8 (27.9, 29.7) 28.5 (26.2, 30.9) .37 .31  28.4 (27.8, 29.0) 27.4 (26.2, 28.5) .104 
Triceps skinfold 
thickness (mm) 23.5 (23.0, 24.0) 23.6 (22.9, 24.3) 24.0 (22.2, 25.8) .64 .87  23.6 (23.1, 24.0) 22.8 (21.9, 23.7) .0682 
Arm fat area (mm2) 9.5 (9.4, 9.6) 9.5 (9.4, 9.7) 9.6 (9.3, 10.0) .33 .45  9.5 (9.4, 9.6) 9.3 (9.1, 9.5) .0157 
Arm muscle area (mm2) 58.7 (57.6, 59.8) 60.2 (58.6, 61.7) 61.5 (57.4, 65.6) .084 .11  59.7 (58.6, 60.7) 56.1 (54.1, 58.1) .0008 
Height (cm) 150.4 (150.1, 150.8) 150.2 (149.7, 150.6) 150.4 (149.2, 151.6) .42 .32   150.4 (150.1, 150.7) 150.0 (149.4, 150.6) .21 
Reported values are untransformed means (95% confidence interval).  All data except baseline BMI were collected in the 2005 
survey.  For women who were pregnant or missing data in 2005, measures from the 2002 survey were substituted.  Baseline BMI 
and covariates were collected from postpartum surveys in 1983-1984.  Models were adjusted for age, assets, total number of past 
pregnancies, income, and menopausal status (except baseline BMI). 
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Table 3.4: Association of FTO and ADRB3 SNPs with overweight and obesity status 
 FTO rs9939609  ADRB3 rs4994 
  Odds Ratio (95% CI) 
p-
value 
  Odds Ratio (95% CI) p-value 
2005 overweight and obese (BMI ≥ 25 kg/m2)  1.30 (1.09, 1.55) .0034  1.33 (1.07, 1.63) .0077 
2005 obese (BMI ≥ 30 kg/m2) 1.31 (1.00, 1.72) .054  1.46 (1.05, 2.02) .023 
1983-84 overweight and obese (BMI ≥ 25 kg/m2) 1.50 (1.06, 2.12) .023   1.27 (1.01, 1.61) .044 
1983-84 obese (BMI≥ 30 kg/m2) is not reported because only 2 people were observed with BMI≥30 kg/m2.  Models 
were adjusted for age, assets, total number of past pregnancies, income, and menopausal status (except 1983-84 
model). 
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Figure 3.1: Longitudinal analysis of BMI using measurements across eight surveys from 
1983-84 to 2005 of A) FTO rs9939609 (p-value .000029) and B) ADRB3 rs4994 (p-value 
.016).  BMI is reported as the least-squares means at each time point. 
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ABSTRACT 
We performed a genome-wide association (GWA) study for HDL-cholesterol (HDL-C), 
triglycerides, LDL-cholesterol (LDL-C), and total cholesterol in a cohort of 1,780 adult 
Filipino women from the Cebu Longitudinal Health and Nutrition Survey (CLHNS).  
Among the ~2.1 million single nucleotide polymorphisms (SNPs) analyzed, the most 
significant associations after adjusting for age, age2, total assets, income, number of 
previous pregnancies, menopausal status, and principal components included rs5882 at 
CETP with HDL-C (P = 4.01 x 10-8) and rs662799 at APOA1 with triglycerides (P = 1.23 
x 10-14).  Evidence of association (P < .05) was observed at eleven loci previously 
described in GWA studies of lipoprotein levels, and evidence for two independent signals 
was detected at LIPC, CETP, and GCKR.  Loci with suggestive evidence of association 
(P < 10-5) and not previously described include Collecting-12 (COLEC12) associated 
with total cholesterol and Tankyrase (TNKS) associated with LDL-C.  These two loci 
have potential biological relevance to lipid metabolism.  The results confirm that even in 
a divergent population with limited power to detect association we can extend the 
evidence of association of many previously reported loci.  The suggestive evidence of 
association of the two novel loci should be the basis for follow-up studies in subsequent 
populations. 
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INTRODUCTION 
Plasma lipoprotein levels are associated with risk of coronary artery disease 
(CAD), one of the leading causes of death worldwide [1].  Low levels of high density 
lipoprotein cholesterol (HDL-C) and high levels of triglycerides and low density 
lipoprotein cholesterol (LDL-C) are associated with increased risk of CAD [2-4].  While 
diet, exercise, weight, alcohol consumption, and smoking affect levels of lipoproteins, 
heritability estimates for lipoprotein concentrations are as high as 75% [5,6]. The 
influence of genetic variants on lipoprotein levels may differ across populations.  For 
these reasons, there has been considerable interest in understanding genetic factors that 
contribute to inter individual variation.  
Recent genome-wide association (GWA) studies in populations of primarily 
European descent have identified many loci that are associated with blood plasma 
lipoprotein levels [7-19].  Some identified loci correspond to previously known genes and 
others suggest new pathways relevant to lipoprotein metabolism .  Despite the large 
number of loci identified in these studies (>30), the associated single nucleotide 
polymorphisms (SNPs) only explain 5-8% of the variation in HDL-C, LDL-C, or 
triglycerides, indicating that most of the heritability of these traits remains to be 
explained [20]. 
 Association studies of lipoprotein levels in Asian populations have replicated 
some but not all loci from European GWA studies [21-23].  Some Asian populations are 
undergoing socio-economic development and lifestyle changes that are increasing CAD 
burden [24].  The environmental differences and the potential differences in genetic 
architecture between ethnic groups within and between European and Asian populations 
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may modify the effect of genetic variants on lipoprotein levels. 
In the current study, we performed a GWA analysis to investigate genetic factors 
influencing lipoprotein and triglyceride levels in mothers from the Cebu Longitudinal 
Health and Nutrition Survey (CLHNS), using data from 1,780 unrelated healthy women 
from Cebu, Philippines. 
 
MATERIALS AND METHODS 
Study population and phenotypes 
We initially evaluated 1,895 healthy Cebu Filipino female participants from the 
ongoing CLHNS, mothers of a 1983 to 1984 birth cohort [25].  Trained field staff 
conducted in-home interviews and collected quantitative anthropometric measurements, 
blood samples for DNA and biomarkers, and comprehensive environmental data 
(available on-line at www.cpc.unc.edu/projects/cebu/).   
Outcomes and covariates were measures were during the 2005 survey.  Lipid 
levels were collected from women who fasted overnight (>8 hours) and were not taking 
statins. Details of the measurement of lipid profiles in this cohort have been reported 
previously [26].  Total cholesterol was determined by enzymatic methods (Beckman 
Diagnostics, Palo Alto, CA) on a CX5 chemistry analyzer, HDL-C was determined using 
a homogenous assay (Genzyme, Exton, PA), and triglyceride (TG) concentrations were 
measured with a glycerol blank as a 2-step reaction (Beckman Coulter Diagnostics, 
Fullerton, CA). LDL-C was determined using the Friedewald formula, except if TG 
exceeded 400 mg/dl then LDL-C was directly determined using a homogenous assay 
(Genzyme, Exton, PA). 
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Except for the correlation between LDL-C and total cholesterol (r2 = .81), the four 
traits show low pair-wise correlation with one another (r2 < .1) (Table 4.1).  Body mass 
index (BMI) was calculated as weight/height2 (kg/m2).  
Informed consent was obtained from all CLHNS subjects, and the University of 
North Carolina Institutional Review Board for the Protection of Human Subjects 
approved the study protocol.  
  
SNP genotyping 
Genome-wide SNP genotyping was performed with the commercial release of the 
Affymetrix Genome-Wide Human SNP Array 5.0.  Genotyping was carried out at the 
Vanderbilt Microarray Shared Resource at Vanderbilt University Medial Center, 
Nashville, TN, using the standard protocol recommended by the manufacturer.  Genotype 
calling was performed using the Birdseed calling algorithm (version 2).  Genotyping was 
attempted on 1,895 unique CLHNS samples, 40 CLHNS duplicates, and 5 HapMap 
CEPH trios (whose genotypes were downloaded from HapMap.org).  After sample 
quality control (QC) checks, ten CLHNS samples could not be genotyped because one 
failed DNA fragmentation and nine failed an array quality control check (DM 
algorithm).  An additional four CLHNS samples were removed after genotyping because 
their overall genotyping call rate was < 97%.  The final Birdseed call rate across 1,881 
samples was 99.6%. 
We applied SNP QC checks in PLINK v1.02 on the 1,881 CLHNS samples that 
were successfully genotyped.  Of the initial 424,670 SNPs, we discarded 16,564 SNPs 
due to poor mapping, call rates < 90%, deviation from Hardy-Weinberg equilibrium (P < 
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10-6), inconsistent genotypes in duplicate samples and Mendelian inheritance errors 
(combined ≥ 3 discrepancies among 40 duplicate pairs and 5 CEPH trios), and/or ≥ 3 
genotype discrepancies with HapMap genotypes. 
Based on identity-by-descent (IBD) and identity-by-state (IBS) estimates 
calculated in PLINK in combination with prior knowledge of the CLHNS samples, 
eighty-one samples were excluded from pairs or trios of likely first-degree relatives 
(either mother/daughter or sisters).  The final sample set consisted of 1,780 CLHNS 
women with available genotypes and phenotypes of lipoprotein levels and covariates 
from the 2005 survey. 
Additional genotyping of 2 SNPs at the APOE locus (rs7412 Arg158Cys and 
rs429358 Cys112Arg) was performed using a TaqMan allelic discrimination assay 
(Applied Biosystems, Foster City, CA).  The genotype success rate for both SNPs was 
>98%, and no discrepancies were observed among 78 duplicate sample pairs per SNP. 
  
SNP imputation 
Using a Hidden Markov Model algorithm implemented in the MACH software 
version 1.0 [27] (www.sph.umich.edu/csg/abecasis/mach/), genotype imputation was 
conducted using 352,264 directly genotyped SNPs polymorphic in both the 60 HapMap 
CEU founders and the 89 combined CHB+JPT samples.  We pooled haplotypes from 
phased chromosomes in these populations to better capture the linkage disequilibrium 
(LD) structure in the CLHNS samples; we have shown previously that the CHB HapMap 
population is a reasonable proxy for the CLHNS cohort [28].  Imputation yielded 
genotype data for 1,878,188 additional SNPs; the 352,264 directly genotyped SNPs were 
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also assigned imputed genotypes in this process.  Out of a now total 2,230,452 SNPs, we 
discarded 150,177 low-quality imputations (Rsq ≤ .3) and 30,351 SNPs with estimated 
minor allele frequencies (MAF) ≤ .01, retaining 2,049,924 imputed SNPs.  For each 
subject, the imputed genotype at each SNP was reported as a dosage value (a continuous 
number between 0 and 2), reflecting the expected number of copies of the arbitrary allele 
at that SNP conditional on the directly observed genotypes in both the subject and all 
other CLHNS subjects and the phased haplotype assignments in the CEU and CHB+JPT 
HapMap samples.  Finally, discrete dosage values of 0, 1 or 2 were assigned for 23,750 
directly genotyped SNPs non-polymorphic in either HapMap populations (and therefore 
not imputed) but with MAF > .01 in the CLHNS samples.  In total, 2,073,674 directly 
genotyped (n = 23,750) and imputed (n = 2,049,924) SNPs were tested for association. 
  
Population substructure 
We used two approaches to consider possible effects of population stratification.  
First, we constructed principal components (PCs) using the software EIGENSOFT 
[29,30] to identify population substructure among our CHLNS subjects.  We used a set of 
13,972 independent SNPs (estimated r2 < .005 between all pairs of SNPs within 1Mb) 
with observed MAF > .05 and 1,571 CHLNS subjects with estimated pair-wise IBD < 0.1 
to construct PCs.  The PCs for the remaining 228 subjects were subsequently calculated 
using these parameter values.  The corresponding eigenvalues for the individual PCs 
were plotted and the “elbow” of the corresponding eigenvalues for the individual PCs 
was used to select seven PCs to be included as covariates in our linear regression 
genotype association analyses to account for genetic ancestry differences among study 
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subjects.  In addition, we tested for an association between each of the first 10 PCs and 
the four outcomes of interest to ensure that any important ancestry explanatory PC were 
included in the analyses (Table 4.2).   
Second, we used the genomic control method to examine systematic p-value 
inflation due to cryptic relatedness between samples not accounted for by the analytic 
adjustment for PCs in the regression analyses. The genomic controls values are .988, 
1.01, 1.01, and 1.00 for HDL-C, LDL-C, triglycerides, and total cholesterol, respectively, 
suggesting good control of the overall family-wise type I error rate. 
 
GWA analysis 
All phenotypes were natural log-transformed to satisfy the model assumption of 
normally distributed residuals, conditional on the covariates. Covariate adjustment was 
made for 7 PCs of population structure, age, age2, total assets, natural log-transformed 
income, number of previous pregnancies (three categories: 0–4, 5–10, >10), and 
menopausal status.  Each of these predictors was significantly associated (P < .05) with at 
least one trait in our sample (Table 4.2). Additional analysis adjusting for BMI excluded 
women who were pregnant at the time of the survey.  Multivariable linear regression 
association analysis was performed using Array Studio version 3.1 (Omicsoft 
Corporation, Research Triangle Park, NC).   We assumed an additive mode of inheritance 
and report β coefficients representing the estimated change in mean transformed trait 
value associated with each additional copy of an allele.  A 1 degree-of-freedom 
likelihood ratio test was used to assess statistical significance.  Quantile-quantile (Q-Q) 
plots, mapping observed versus expected –log10(P values), and Manhattan plots were 
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constructed to graphically display results across the genome and to help assess for any 
cumulative inflation or deflation of statistical significance estimates compared to 
expectation under the null hypothesis.  Conditional analysis was performed by re-testing 
all SNPs with a 2 Mb region centered on the SNP representing the strongest primary 
signal using genotypes of the main effect SNP as an additional covariate in the linear 
regression. 
 
APOE haplotype analysis 
Haplotypes were estimated using Haplo.Stats [31] (Version 1.4.3 
http://mayoresearch.mayo.edu/mayo/research/schaid_lab/software.cfm) and correspond 
to the three common protein isoforms of apolipoprotein E (APOE), encoded by the ε2, 
ε3, and ε4 alleles of the APOE gene. We used analysis of covariance (ANCOVA) models 
to test whether APOE haplotype was associated with the lipoprotein phenotypes, 
adjusting for the same covariates as the genome wide analysis. APOE haplotypes were 
tested using 2 approaches: 1) collapsing into three categories of the ε2 carriers, ε3/ε3, and 
the ε4 carriers, excluding ε2/ε4 individuals; and 2) the six estimated haplotypes. We used 
2- and 5-degree of freedom F tests for these two approaches, respectively. 
  
Selection of previously reported SNPs 
To test evidence of association with previously reported loci, we selected one 
SNP from each loci reported in GWA studies with P < 5 x 10-8.  When multiple non-
independent SNPs were reported for a given locus we included the most strongly 
associated one from the previous reports.  If two signals were reported for a locus, we 
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also chose a SNP to represent the second signal.  If a previously reported SNP was not 
present in our dataset, we sought to identify a proxy SNP in high LD (r2 > .8 in both CEU 
and CHB+JPT, HapMap Release 22).  
 
RESULTS 
We tested 2,073,674 SNPs for association with plasma levels of HDL-C, 
triglycerides, LDL-C, and total cholesterol in 1,780 Filipino women in the CLHNS.  
Basic descriptive characteristics of the cohort are summarized in Table 4.3.  GWA 
analyses for all lipoprotein levels were adjusted for 7 PCs of population structure, age, 
age2, total assets, natural log-transformed income, number of previous pregnancies, and 
menopausal status is summarized in Figure 4.1.  Q-Q plots, mapping observed versus 
expected –log10 (P values), show little cumulative inflation or deflation of statistical 
significance estimates compared to expectation under the null hypothesis (Figure 4.2).    
The CLHNS GWA results support ten loci previously described in GWA studies.  
We chose a single previously reported SNP from each locus and defined positive 
evidence for replication in CLHNS as P < .05 and an effect in the same direction as 
observed in the original study (Table 4.4).  The CLHNS study supports three previously 
reported loci associated with HDL-C at MMAB/MVK, LIPC, and CETP, six loci 
associated with triglycerides at ANGPTL3/DOCK7, GCKR, LPL, TRIB1, APOA1, and 
LIPC, and two loci associated with LDL-C at HMGCR and HNF1A.  No loci previously 
reported to be associated with total cholesterol were significant in the CLHNS.  Several 
of the loci previously reported for one trait also showed evidence of association (P < .05) 
with other traits in the CLHNS (Table 4.4).   
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For each of the ten previously reported loci with evidence of association in the 
CLHNS, we performed conditional analyses to evaluate whether any additional SNPs 
were associated with an outcome after accounting for the primary associated SNP.  
Evidence from these analyses suggests the presence of secondary association signals with 
HDL-C at both LIPC and CETP, consistent with previous reports [12].  For the LIPC 
locus, we observed a P value of .0047 for rs10468017, the SNP representing the primary 
previously reported signal, and a P value of 2.5 x 10-5 for rs2070895, the SNP from the 
previously reported secondary signal.  When we adjusted for both of these SNPs, there 
was still a strong association with rs2043085 in the location of the first signal (P = 2.8 x 
10-6) and with rs8023503 in the second signal (P = 6.6 x 10-7).  These two SNPs are the 
most highly associated in the CLHNS data for this locus.  For the SNP reported as the 
CETP first signal (rs173539), we did not have a genotyped or imputed proxy in high LD 
(r2 >.8).  However, after correcting for the second signal (rs289714 for which we 
observed a P value of 1.2 x 10-6), there was still an association with rs711752.  This SNP 
is in r2 = .5 with rs173539 in the CEU HapMap population, and is the most significant 
SNP for what we believe is a proxy, albeit not perfect, for the first signal (P = 5.6 x 10-7).   
For the GCKR locus and association with triglycerides, the previously reported SNP 
rs1260326 had a P value of .0019 in the CLHNS.  After correcting for this SNP, we still 
observed association with rs814295, which had a more significant association of P = 1.4 
x 10-7 in the original analysis. 
A representative SNP (r2 < .8) for the previously reported LDL-C association at 
the APOE locus was not genotyped or imputed in the CLHNS.  We independently 
genotyped in 1656 CLHNS women the two SNPs (rs429358 and rs7412) that compose 
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the common ApoE haplotypes (ε2, ε3, and ε4) [32].  Estimated haplotype frequencies 
were .11, .80, and .08 for ε2, ε3, and ε4, respectively.  The overall genotype frequencies 
were .01, .19, .02, .64, .13, and .01 for ε2/ε2, ε2/ε3, ε2/ε4, e3/e3, ε3/ε4, and ε4/ε4, 
respectively.  The P value for association between the 3-category ApoE haplotype 
variable and LDL-C was strongly significant (P < .0001).  In Bonferroni-corrected post 
hoc pair-wise tests, the ε4 carriers had significantly higher LDL-C levels than the ε3 
homozygotes and ε2 carriers (P < .0001 and P = .0068).  The ε3 homozygotes were 
significantly higher than the ε2 carriers (P < .0001).  Associations with total cholesterol 
and HDL were also significant (P < .05), but not with triglycerides (Table 4.5).  When the 
haplotypes were analyzed as six categories, associations with LDL-C were highly 
significant (P < .0001) and approximately linear when ordered ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, 
ε3/ε4, and ε4/ε4 with the least-square adjusted mean log-LDL-C levels of 4.41 (± .05), 
4.59 (± .02), 4.70 (± .05), 4.76 (± .01), 4.81 (± .02), and 4.91 (± .07), respectively. The 
least-square adjusted mean log-LDL-C level correspond to raw LDL-C values of 87.1, 
102.4, 114, 121.3, 127, and 140.4, respectively.  As with the three-category haplotype 
analysis, associations were also observed for triglycerides, HDL-C, and total cholesterol 
(Table 4.5).  Together, these association results are consistent with what have been 
observed by others [32]. 
 For each of the four lipoprotein traits, we observe suggestive evidence of 
association (P < 10-5) at loci not described previously (Table 4.6).  Most notably, SNPs in 
intron 3 of tankyarase (TNKS) are associated with LDL-C (P = 7.4 x 10-6) and SNPs in 
intron 2 of collectin-12 (COLEC12) are associated with total cholesterol (P = 5.3 x 10-6).  
We performed conditional analyses on all the most significant main effect associations to 
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evaluate whether any additional SNPs were associated with a given outcome after 
accounting for the associated SNP.  We found no evidence for a strong secondary signal 
at these loci.  
Finally, we tested whether genotype associations with lipoprotein levels are 
mediated by BMI to further evaluate the characteristics of loci exhibiting evidence of 
association. However, adjusting for BMI did not considerably attenuate or increase the 
evidence of association with most variants, suggesting the changes in lipoprotein levels 
due to these variants and obesity are independent (data not shown).  However, for the 
locus ANGPTL3-DOCK7 with triglycerides we observed a change in P value from .04 
with a ß of .038 ± .018 to .006 with a ß of .048 ± .017 after adjusting for BMI.  However, 
this change in P value may be the result of stochastic variation.  
 
DISCUSSION 
We performed the first GWA study for lipoprotein levels in a cohort from the 
Philippines, a country undergoing socio-economic and nutrition transition. The strongest 
main effect association in the CLHNS was observed for the APOA1-APOC3-APOA4-
APOC2 locus for triglycerides (rs662799, P = 1.2 x 10-14), one of the most commonly 
replicated triglyceride signals. Additionally, these results support association of other 
loci: MMAB/MVK, LIPC, and CETP with HDL-C; ANGPTL3/DOCK7, GCKR, LPL, 
TRIB1, APOA1, and LIPC with triglycerides; and HMGCR, HNF1A, and APOE with 
LDL-C. Many of these genes were initially identified in candidate gene studies and have 
shown evidence of association across many populations.  Together, all of the previously 
reported SNPs for each trait explain 4.2%, 5.5%, 1%, .5% of the variation for HDL–C, 
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triglycerides, LDL-C, and total cholesterol, respectively, leaving most of the heritability 
to be explained.  Despite a lack of significant statistical association, the direction of 
association was consistent with previous reports for many of the other previously 
reported loci.  Many of the SNPs that show association with the original reported trait are 
also associated with another trait, consistent with the correlations between traits.  Lack of 
trait association in our study for some SNPs that have been previously reported likely 
primarily reflects a smaller sample size but may also be due to different LD between 
analyzed SNPs and the underlying functional variant. Using our replication criteria, the 
study had > 80% power to detect SNPs that explained .44% of the total variation in our 
lipoprotein traits after adjustment for covariates. 
Compared to Western populations, CLHNS participants have relatively HDL-C 
values. HDL-C levels have been previously reported to be lower in Asians compared to 
European populations, even though Asians are less obese [33].  Low HDL-C is defined as 
< 50 mg/dL, and the mean level in the CLHNS women was 40.9 mg/dL, similar to that 
reported in another study of Filipino women [34].  Despite differing HDL-C levels in the 
CLHNS population compared to the previous European populations studied, we have 
replicated several previously reported loci associated with plasma levels of HDL-C.  For 
the CETP, LIPC, and MMAB/MVK loci, the CLHNS samples have slightly higher allele 
frequencies for the HDL-C lowering alleles. These may contribute slightly to a decrease 
the population mean HDL-C because the risk alleles are affecting more members of the 
population.  We further examined individuals in the CLHNS with isolated low HDL-C 
and observed similar results (data not shown).  These results suggest that certain loci still 
seem important even in a different environmental/genetic background. 
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Some of the associations described first in European populations have also been 
replicated in other Asian populations.  Hiura et al. conducted a GWA study for HDL-C in 
900 Japanese individuals and observed evidence of association with CETP, but not with 
other previously identified loci [22].  Tai et al. examined the association with LDL-C, 
HDL-C and total cholesterol for four polymorphisms identified in previous GWA study 
of lipoproteins in 2932 Malay participants from Singapore [21].  The authors observed 
evidence of association for TRIB1 with total cholesterol and LDL-C, but not HDL-C and 
CILP2/PBX4 with HDL-C, a trait not previously reported to be associated with this locus. 
Of these two sets of findings, only the association of CETP with HDL-C is consistent 
with our results. 
Among the loci with suggestive evidence of association (P < 10-5) two signals are 
located within genes that that have potential biological relevance to metabolism, 
Collectin-12 (COLEC12) and Tankyrase (TNKS). SNPs within intron 2 of COLEC12 are 
associated with total cholesterol and LDL-C levels.  COLEC12 mediates the recognition, 
internalization and degradation of oxidatively modified LDL by vascular endothelial cells 
[35]. SNPs within intron 3 of TNKS are associated with LDL-C and total cholesterol.   
TNKS-deficient mice exhibit an increase in energy expenditure, fatty-acid oxidation, and 
insulin-stimulated glucose utilization, and adiposity is substantially decreased even with 
excessive food intake [36]. While these genes seem biologically plausible, the evidence 
of association needs to be confirmed in additional populations. Each of these loci account 
to ~1% of the estimated proportion of variance in the CLHNS.   
Our results show that multiple genetic risk factors identified in other world 
populations are also associated with lipid traits in Filipinos.  These observations should 
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form the basis of understanding the mechanistic roles of these loci and identifying 
functional or causative variants. 
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Table 4.1. Spearman’s correlations between traits measured in 1780 CLHNS women 
 
 
 
TG LDL-C Total Cholesterol
HDL-C 0.038 0.016 0.082
TG - 0.00058 0.100
LDL-C - - 0.811
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Table 4.2. Effect of potential covariates on lipoprotein outcomes for 1798 CLHNS 
women  
 
 
Covariates 
included in 
tests of effect 
P-value for effect 
Log HDL-C Log TG Log LDL-C Log Total Cholesterol 
Age - .0040 <.0001 <.0001 <.0001 
Age2 Age .40 .00020 <.0001 <.0001 
Assets Age, Age2 <.0001 <.0001 <.0001 <.0001 
Log income Age, Age2 .0019 <.0001 <.0001 <.0001 
#Pregnancies 
(3 categories) Age, Age
2
 
<.0001 .076 .00030 <.0001 
Menopause Age, Age2 .016 .11 .27 .16 
PC1 Age, Age
2
, All 
other PCs 
.0001 .60 .0679 .0070 
PC2 Age, Age
2
, All 
other PCs 
.0028 .15 .1001 .88 
PC3 Age, Age
2
, All 
other PCs 
.041 .19 .77 .996 
PC4 Age, Age
2
, All 
other PCs 
.34 .22 .34 .81 
PC5 Age, Age
2
, All 
other PCs 
.31 .28 .54 .59 
PC6 Age, Age
2
, All 
other PCs 
.27 .65 .0085 .014 
PC7 Age, Age
2
, All 
other PCs  
.0277 .84 .44 .18 
PC8 Age, Age
2
, All 
other PCs 
.61 .79 .24 .19 
PC9 Age, Age
2
, All 
other PCs 
.27 .44 .999 .98 
PC10 Age, Age
2
, All 
other PCs 
.74 .15 .39 .31 
All factors and outcomes correspond to the 2005 survey. P-values in bold denote P < .05.  
PC1-PC10 are the Eigenstrat principal components; PC1-PC7 were included in SNP 
association analyses. 
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Table 4.3. Descriptive characteristics of CLHNS women 
 
Trait N Mean ± SD 
LDL-cholesterol (mg/dL) 1780 119.6 ± 33.7 
HDL-cholesterol (mg/dL) 1780 40.9 ± 10.37 
Triglycerides (mg/dL) 1780 130.8 ± 83.5 
Total cholesterol (mg/dL) 1780 186.8 ± 39.3 
Age (years) 1780 48.4 ± 6.1 
Total number of pregnancies  1780 6.5 ± 3.0 
Body mass index (kg/m2)* 1768 24.3 ± 4.4 
Values correspond to the 2005 survey.  
*BMI reported only for women who were not pregnant. 
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Table 4.4. Evidence of association in CLHNS women at previously reported GWA loci 
 
Freq
SNP Gene Chr Pos Allele 1a Allele 2 Allele 1 P value (β ± s.e.m.) P value (β ± s.e.m.) P value (β ± s.e.m.) P value
HDL-C
rs4846914 GALNT2 1 228362314 A G 0.29 0.36 .008 (.009) 0.34 -.017 (.017) 0.75 .003 (.01) 0.92
rs6754295b APOB 2 21059688 G T 0.69 0.60 -.005 (.010) 0.19 .024 (.018) 0.20 -.014 (.011) 0.43
rs10503669d LPL 8 19891970 A C 0.05 0.90 .002 (.020) 0.023 -.088 (.039) 0.088 -.039 (.023) 0.032
rs1883025 ABCA1 9 106704122 C T 0.58 0.35 .009 (.009) 0.045 .036 (.018) 0.17 -.015 (.011) 0.83
rs471364 TTC39B 9 15279578? T C 0.97 0.24 .032 (.027) 0.46 .039 (.052) 0.51 .02 (.031) 0.22
rs7395662b MADD-FOLH1-NR1H3 11 48475469 G A 0.21 0.80 -.003 (.010) 0.92 .002 (.020) 0.75 -.004 (.012) 0.74
rs174547 FADS1-FADS2-FADS3 11 61327359 T C 0.07 0.25 -.020 (.017) 0.23 .039 (.033) 0.21 -.024 (.019) 0.41
rs964184 APOA1-APOC3-APOA4-APOA5 11 116154127 C G 0.76 0.053 .019 (0.01) 2.0E-13 -.14 (.019) 0.53 .007 (.011) 0.12
rs10892044 APOA1-APOC3-APOA4-APOA5* 11 116272109 C T 0.02 0.80 .007 (.027) 0.033 -.112 (.052) 0.57 -.018 (.031) 0.26
rs2338104 MMAB-MVK 12 108379551 G C 0.39 0.02 .021 (.009) 0.88 -.003 (.017) 0.015 .024 (.010) 0.0069
rs10468017 LIPC 15 56465804 T C 0.21 0.0047 .031 (.011) 0.0076 .057 (.021) 0.029 .027 (.013) 7.8E-04
rs2070895 LIPC* 15 56511231 A G 0.37 2.5E-05 .046 (.011) 0.028 .047 (.021) 0.44 .01 (.013) 0.014
rs289714 CETP* 16 55564952 A G 0.80 1.2E-06 .083 (.017) 0.49 -.023 (.033) 0.11 .031 (.020) 0.015
rs2271293 LCAT-CTCF-PRMT8 16 66459571 A G 0.04 0.12 .034 (.022) 0.98 -.001 (.043) 0.86 .005 (.025) 0.39
rs4939883 LIPG 18 45421212 C T 0.86 0.072 .022 (.012) 0.73 .008 (.023) 0.97 .0004 (.014) 0.46
rs2967605 ANGPTL4 19 8375738 C T 0.42 0.064 .021 (.011) 0.085 -.037 (.022) 0.44 .010 (.013) 0.59
rs7679 PLTP 20 44009909 T C 0.97 0.091 -.044 (.026) 0.75 -.016 (.050) 0.039 .062 (.03) 0.53
rs173539 CETP N/A
rs1800961 HNF4A N/A
Triglycerides
rs1167998b ANGPTL3-DOCK7 1 62704220 A C 0.71 0.11 -.015 (.009) 0.035 .038 (.018) 0.79 .003 (.011) 0.45
rs4846914e GALNT2 1 228362314 A G 0.29 0.36 .008 (.009) 0.34 -.017 (.017) 0.75 .003 (.01) 0.92
rs7557067 APOB 2 21061717 A G 0.30 0.58 .005 (.009) 0.17 -.025 (.018) 0.19 .014 (.011) 0.42
rs1260326 GCKR 2 27584444 T C 0.42 0.67 .003 (.009) 0.0019 .055 (.018) 0.86 .002 (.011) 0.18
rs714052 MLXIPL 7 72502805 A G 0.89 0.79 .0038 (.014) 0.19 .035 (.027) 0.42 .013 (.016) 0.25
rs7819412 XKR6-AMAC1L2 8 11082571 A G 0.10 0.084 -.0253 (.0146) 0.042 -.057 (.028) 0.71 -.006 (.017) 0.24
rs12678919 LPL 8 19888502 A G 0.95 0.87 -.003 (.020) 0.019 .091 (.039) 0.081 .04 (.023) 0.027
rs2954029 TRIB1 8 126560154 A T 0.44 0.81 -.002 (.008) 0.030 .035 (.016) 0.39 .008 (.010) 0.15
rs174547 FADS1-FADS2-FADS3 11 61327359 C T 0.93 0.25 .020 (.017) 0.23 -.039 (.033) 0.21 .024 (.019) 0.41
rs964184 APOA1-AOC3-APOA4-APOA5 11 116154127 G C 0.24 0.053 -.019 (.010) 2.0E-13 .14 (.019) 0.53 -.007 (.011) 0.12
rs4775041d LIPC 15 56461987 C G 0.19 0.005 .030 (.011) 0.0084 .054 (.021) 0.021 .028 (.012) 5.5E-04
rs17216525 NCAN-CILP2-PBX4 19 19523220 C T 0.93 0.96 .001 (.016) 0.94 .002 (.031) 0.20 -.024 (.019) 0.45
rs7679 PLTP 20 44009909 C T 0.03 0.091 .044 (.026) 0.75 .016 (.050) 0.039 -.062 (.030) 0.53
rs157580b CEACAM16-TOMM40 N/A
HDL-C Triglycerides LDL-C Total Cholesterol
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LDL-C
rs11206510 PCSK9 1 55268627 T C 0.94 0.087 .032 (.018) 0.51 .024 (.035) 0.61 .011 (.021) 0.43
rs12740374 CELSR2-PSRC1-SORT1 1 109619113 G T 0.95 0.24 -.026 (.022) 0.15 .06 (.042) 0.062 .046 (.025) 0.10
rs4844614c CR1L 1 205941798 T G 0.23 0.48 .009 (.013) 0.98 .001 (.025) 0.90 -.002 (.015) 0.69
rs515135 APOB 2 21139562 C T 0.92 0.18 .022 (.016) 0.38 -.026 (.030) 0.70 .007 (.018) 0.74
rs3846663 HMGCR 5 74691482 T C 0.54 0.63 -.004 (.008) 0.51 .011 (.016) 0.034 .020 (.010) 0.036
rs1501908 TIMD4-HAVCR1 5 156330747 C G 0.65 0.85 .002 (.009) 2.6E-04 .063 (.017) 0.57 .006 (.010) 0.059
rs12670798b DNAH11 7 21573877 C T 0.56 0.15 .018 (.012) 0.77 .007 (.024) 0.67 .006 (.014) 0.31
rs174570b FADS3-FADS2 11 61353788 C T 0.16 0.96 -.001 (.014) 0.14 .04 (.027) 0.23 -.020 (.016) 0.69
rs2650000 HNF1A 12 119873345 A C 0.42 0.71 .003 (.009) 0.96 .001 (.017) 0.014 .025 (.010) 0.023
rs10401969 NCAN-CILP2-PBX4 19 19268718 T C 0.95 0.34 -.029 (.031) 0.21 .074 (.059) 0.59 -.019 (.035) 0.82
rs10402271f BCAM 19 50021054 G T 0.17 0.82 .003 (.011) 0.24 .025 (.021) 0.040 -.026 (.013) 0.13
rs6102059 MAFB 20 38662198 C T 0.58 0.83 -.002 (.009) 0.20 -.022 (.017) 0.63 -.005 (.010) 0.61
rs6544713 ABCG8 N/A
rs4420638 LDLR N/A
rs2075650f TOMM40 N/A
rs6511720 APOE-APOC1-APOC4-APOC2 N/A
rs4803750f BCL3 N/A
Total Cholesterol
rs10903129b TMEM57 1 25641524 G A 0.16 0.62 -.006 (.012) 0.49 -.015 (.022) 0.97 -.001 (.013) 0.82
rs10889353b DOCK7 1 62890784 A C 0.76 0.24 -.012 (.010) 0.057 .036 (.019) 0.80 -.003 (.011) 0.78
rs646776b SARS-CELSR2-MYBPHL 1 109620053 T C 0.95 0.25 -.025 (.022) 0.16 .059 (.041) 0.068 .045 (.025) 0.10
rs693b APOB 2 21085700 A G 0.08 0.14 .024 (.016) 0.42 .025 (.030) 0.55 .011 (.018) 0.21
rs3846662b GCNT4-HMGCR-POLK 5 74686840 G A 0.55 0.60 -.004 (.008) 0.51 .011 (.016) 0.078 .017 (.010) 0.069
rs6987702b TRIB1-FAM84B 8 126573908 C T 0.64 0.18 .014 (.011) 0.22 -.024 (.020) 0.31 .012 (.012) 0.56
rs174570b FADS3-FADS2 11 61353788 C T 0.16 0.96 -.001 (.014) 0.14 .04 (.027) 0.23 -.02 (.016) 0.69
rs2304128b NCAN-ZNF104 19 19607151 G T 0.96 0.66 .015 (.035) 0.51 .043 (.067) 0.88 -.006 (.040) 0.60
rs6756629b ABCG5 N/A
rs2228671b LDLR N/A
 
Chromosomal positions are NCBI Build 36.  SNPs are arranged in ascending chromosomal order.   
SNPs previously reported to be associated with lipoprotein levels in GWA studies (P < 10-8) are included.  SNPs are from Kathiresanat al. 2009 unless otherwise indicated. Bold 
represents SNPs with a P value < .05 and direction of effect consistent with previous reports.  
 
*Asterisks represent second signals reported in Kathiresan et al. 2009. 
a Allele associated with increased trait value in prior report 
b Aulchenko et al. 2009 
c Sabatti et al. 2009 
d Willer et al. 2008 
e Kathiresan et al. 2008 
f Sandhu et al. 2008
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Table 4.5. APOE haplotype association analysis in CLHNS 
 
APOE 
haplotype 
Genotype 
frequency HDL-C Triglycerides LDL-C 
3 categories  
ε2 carriers .20 3.71 (0.01) 4.76 (0.03) 4.57 (0.02) 
ε3/ ε3 .64 3.67 (0.01) 4.72 (0.02) 4.76 (0.01) 
ε4 carriers .14 3.66 (0.02) 4.73 (0.03) 4.82 (0.02) 
P value  
.019 .53 <.0001 
 
 
   
6 categories  
ε2/ ε2 .01 3.78 (0.05) 5.11 (0.1) 4.41 (0.06) 
ε2/ ε3 .19 3.71 (0.02) 4.73 (0.03) 4.59 (0.02) 
ε2/ ε4 .02 3.67 (0.05) 114.01 (5.78) 4.7 (0.05) 
ε3/ ε3 .64 3.67 (0.01) 4.72 (0.02) 4.76 (0.01) 
ε3/ ε4 .13 3.65 (0.02) 4.73 (0.03) 4.81 (0.02) 
ε4/ ε4 .01 3.75 (0.06) 4.81 (0.12) 4.91 (0.07) 
P value  .035 .0008 <.0001 
Least-square means (SE) are shown. 
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Table 4.6.  SNPs with suggestive evidence of association with lipoprotein levels in 
CLHNS (P < 10-5) 
Freq
SNP Gene Chr Pos Allele1 Allele2 Allele1 P value (β ± s.e.m.) P value (β ± s.e.m.) P value (β ± s.e.m.) P value (β ± s.e.m.)
TG
rs17023681 CNTN4 3 2978279 T G 0.72 0.87 -0.002 (0.013) 4.1E-06-0.114 (0.025) 0.50 -0.010 (0.015) 0.0088 -0.027 (0.010)
rs7644509 Chr3q26.1 3 1.68E+08 C G 0.85 0.21 0.015 (0.012) 6.3E-06-0.104 (0.023) 0.88 0.002 (0.014) 0.22 -0.012 (0.010)
rs2453464 PCSK5 9 78109296 A G 0.16 0.11 -0.020 (0.012) 5.5E-06 0.107 (0.024) 0.45 -0.011 (0.014) 0.38 0.009 (0.010)
rs1893838 ZBTB7C 18 44132146 T C 0.65 0.29 -0.010 (0.009) 5.0E-06-0.078 (0.017) 0.16 -0.014 (0.010) 7.1E-04-0.024 (0.007)
HDL
rs17548357 BIRC6 2 32510121 G A 0.99 8.5E-06 0.174 (0.039) 0.93 -0.007 (0.075) 0.80 0.011 (0.045) 0.28 0.034 (0.032)
rs1544857 SLC4A10 2 1.62E+08 G C 0.83 1.6E-06 0.056 (0.012) 0.88 -0.003 (0.022) 0.56 0.008 (0.013) 0.13 0.014 (0.009)
rs3739440 PAX5 9 37021074 C T 0.84 5.4E-06 0.059 (0.013) 0.79 0.007 (0.025) 0.053 -0.029 (0.015) 0.71 -0.004 (0.011)
rs11227643 11q13.1 11 66516071 G C 0.78 7.7E-06-0.055 (0.012) 0.27 0.026 (0.024) 0.38 -0.012 (0.014) 0.18 -0.013 (0.010)
rs138779 TOM1 22 34042177 T C 0.59 1.9E-07 0.046 (0.009) 0.66 -0.008 (0.017) 0.72 0.004 (0.010) 0.12 0.011 (0.007)
LDL
rs4570159 TNKS 8 9568712 G A 0.69 0.17 0.012 (0.009) 0.16 -0.025 (0.017) 7.4E-06 0.046 (0.010) 9.4E-05 0.029 (0.007)
rs4787103 A2BP1 16 7982718 G A 0.64 0.66 -0.005 (0.012) 0.45 0.017 (0.023) 6.5E-06-0.061 (0.014) 5.6E-04-0.033 (0.010)
TC
rs1414513 HLX 1 2.19E+08 A G 0.90 0.097 -0.024 (0.015) 0.080 -0.049 (0.028) 6.1E-04-0.057 (0.017) 7.5E-06-0.053 (0.012)
rs551314 TBA3C 13 18620448 A C 0.98 0.32 0.038 (0.039) 0.11 0.118 (0.074) 1.2E-05 0.193 (0.044) 4.7E-06 0.142 (0.031)
rs2032158 COLEC12 18 349196 C T 0.94 0.23 -0.022 (0.018) 0.019 -0.080 (0.034) 2.9E-04-0.074 (0.020) 5.3E-06-0.065 (0.014)
HDL TG LDL Total Cholesterol
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Figure 4.1. Genome-wide evidence of association with lipoproteins in 1,780 CLHNS 
women.  A HDL-C, B. triglycerides, C. LDL-C, and D. total cholesterol levels. Each plot 
represents 2,073,674 SNPs that were tested for association adjusted for age, age2, number 
of previous pregnancies, menopause status, and 7 PCs for population substructure. 
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Figure 4.2. Quantile-Quantile plots for tests of association with lipoproteins in 1,780 
CLHNS women A. HDL-C, B. triglycerides, C. LDL-C, and D. total cholesterol.  Dotted 
lines indicate 95% confidence intervals  
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ABSTRACT 
Recent genome-wide association studies have identified several novel risk loci for plasma 
lipoprotein levels.  One of these loci, GALNT2, contains single nucleotide polymorphisms 
(SNPs) in intron one associated with high density lipoprotein cholesterol (HDL-C) (P < 5 
x 10-8).  Our goal is to identify functional variant(s) at this locus responsible for the 
association signal.  Because no other genes are located close to the associated SNPs, we 
hypothesize that a functional variant(s) acts on GALNT2 or a putative novel intronic 
transcript.  We identified a total of 24 SNPs that are in at least moderate linkage 
disequilibrium (LD) (r2 >.5) with an HDL-C associated SNP.  Additionally, we 
determined that a 21 bp deletion, rs6143660, was in strong LD (r2=.88) with an 
associated SNP and had a minor allele frequency of .36.  Of these 25 variants, five 
(rs2144300, rs4846913, rs6143660, rs17315646, rs4846914) are located within a 1 kb 
region that overlaps experimental functional annotation of open chromatin (DNase 
hypersensitivity and FAIRE) and histone modifications (H3K4me3) in a human 
hepatocellular carcinoma cell line (HepG2), suggesting regulatory function.  To test the 
effects of the haplotypes on transcriptional activity, the 1 kb segment was divided into 
two separate regions.  Each region was cloned in both the forward and reverse orientation 
into a luciferase reporter vector and transfected into HepG2 cells.  Region 1 (rs2144300, 
rs4846913, rs6143660) demonstrated an approximate two-fold increase in transcriptional 
activity for one haplotype containing the deletion of rs6143660, the T allele of 
rs2144300, and the A allele of rs4846913, which have been associated with increased 
HDL-C levels.  The effect was consistent in both a promoterless and a minimal promoter 
vector in both the forward and reverse orientation (P < .02).  Region 2 did not show any 
101 
allelic differences in transcriptional activity (P  > .05) in either the forward and reverse 
orientation in a minimal promoter luciferase reporter vector.  These results suggest that 
the 21 bp deletion, rs4849913, and/or rs2144300 may act to increase the transcriptional 
activity of GALNT2 or an unknown novel intronic transcript to increase HDL-C. 
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INTRODUCTION 
Coronary artery disease (CAD) is the leading cause of death in the United States 
in both men and women [1].  Low levels of high density lipoprotein cholesterol (HDL-C) 
are associated with increased risk of CAD, thus understanding the basis of inter-
individual variation in HDL-C is essential to understanding CAD [2].  Many factors 
influence HDL-C, including diet, physical activity, and genetics [3].  However, most of 
the heritability of HDL-C is left to be explained [4].  
In recent genome-wide association (GWA) studies of Caucasian populations 
[5,6], a novel locus in intron one of GALNT2 was identified to be strongly associated (P 
< 9.4 x 10-8) with HDL-C levels as well as triglyceride levels.  Additionally, an 
unpublished meta-analysis of approximately 100,000 Caucasian individuals confirms the 
association with HDL-C levels with P values as significant as 2.97 x 10-21 for rs4846914 
(Teslovich et al., Abstract American Society for Human Genetics 2009).  For each 
additional A allele of the single nucleotide polymorphism (SNP) rs4846914, individuals 
have an ~1.15 mg/dL increase of HDL-C [5].  However, in the GWA study of the 
CLHNS women (Chapter IV), GALNT2 SNPs were not associated (P > .05) with HDL-C 
or triglycerides (index SNP rs4846914, P = .36 for HDL-C in the direction of effect 
previously reported and P = .34 for triglycerides in the opposite direction of effect 
previously reported).  
The genomic region around the association signal contains few genes upon which 
these associated SNPs may be acting (Figure 5.1A).  The signal is within intron one of 
GALNT2, N-acetylgalactosaminyltransferase 2.  Other genes are relatively far away from 
the associated region.  The nearest genes are PGBD5 and KIAA0133.  PGBD5, piggyBac 
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transposable element derived 5, is 148 kb downstream of the association signal.   PGBD5 
appears to have been derived from the piggyBac transposons and has no known function. 
KIAA0133, which encodes hypothetical protein LOC9816, is ~407 kb upstream of the 5’ 
untranslated region (UTR) of GALNT2.  Alternatively, the HDL-C-associated variants 
may affect an unidentified or more distant transcript. 
The association signal spans a moderately small region of at least 15 kilobases 
(kb) and contains relatively few variants.  Of the reported SNPs within GALNT2, eight 
are highly associated with HDL-C levels (P < 1 x10-7) and are in strong linkage 
disequilibrium (r2 >.8) with each other [7,8; 
http://www.sph.umich.edu/csg/abecasis/public/lipids2008/]. These characteristics make 
this region a prime candidate for identifying the functional variant(s).  
There are many potential molecular mechanisms for a functional variant(s).  In 
the simplest scenario, a SNP allele can alter a key amino acid residue that is critical to 
protein function and activity.  However, like many of the recent association signals 
identified in GWA studies, the associated SNPs in GALNT2 are located in non-coding 
sequence, suggesting that non-coding variation plays an important role in common 
disease.  These non-coding SNPs may influence biological processes by reducing 
transcription factor binding affinity or modifying RNA splicing. 
Most DNA is wound around a histone core, forming nucleosomes.  When DNA is 
in this state it is inaccessible to transcription factors, RNA polymerase, or trans-
regulatory factors.  DNA segments that are actively regulating transcription are 
characterized by depletion of nucleosomes from the chromatin.  The distribution of 
nucleosomes along DNA can be mapped using DNase I hypersensitivity [9] and 
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Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE) [10]. Additionally, in 
eukaryotes modifications of histone tails such as histone H3 trimethylation at lysine 4 
(H3K4me3) are associated with active chromatin and gene expression [11].  These 
modifications can differ between tissues, making it valuable to study the specific tissue in 
which a gene may act.  
To identify additional HDL-C-associated variant(s) that may be responsible for 
the association signal, we used LD data generated in our laboratory from resequencing 
the association region as well as data from the 1000 Genomes project 
(http://browser.1000genomes.org).  We then used computational and experimental data of 
open chromatin and histone modifications in the human hepatocellular carcinoma cell 
line (HepG2) to identify regions that are highly suggestive of regulatory function.  We 
tested variants in the identified regions using a luciferase reporter assay to identify effects 
on transcription.  One or more variants may act to increase or decrease the transcription 
of GALNT2 or an unknown transcript.  
 
MATERIALS AND METHODS 
Resequencing GALNT2 exon 2 
Forty-eight unrelated individuals from the Finland-United States Investigation of 
NIDDM Genetics (FUSION) [12] were resequenced for 538 bp including exon 2, 291 bp 
upstream and 153 bp downstream. Primers were selected using Primer3 software [13; 
http://www.genome.wi.mit.edu/genome_software/other/primer3.html]: Forward: 5’-
CCCTGGGAGTTTTTGGAGTA-3’ and Reverse: 5’-ACTGCTTTGCCAACTTCCAT-
3’.  Sequencing was performed at the University of North Carolina, Chapel Hill 
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automated DNA sequencing facility on an ABI Prism 3730 (Applied Biosystems, Foster 
City, CA, USA) using the Big Dye Terminator Kit.  Sequences were compared using 
Sequencher 4.2.2 (Gene Codes Corporation, Ann Arbor, MI, USA). 
Additional sequencing of the GALNT2 exons and the ~15 kb associated region 
defined by recombination hotspots was performed on 188 individuals at the J. Craig 
Venter Institute as part of the NHLBI genotyping and re-sequencing program.  The 188 
individuals were selected from the extremes of the HDL-C distribution among FUSION 
individuals without type 2 diabetes and not taking lipid-lowering medications.  
 
Construction of luciferase reporter plasmids 
Four individuals from the FUSION samples who were homozygous for the alleles 
of the desired haplotypes were used as templates for PCR.  Primers were selected using 
Primer3 software.  The PCR primers were as follows: Region 1 Forward: 5’-
GGCTCTGGCAAAGTGTCTTG-3’ Reverse: 5’-TGAATTTCTCCGGTTGACCT-3’, 
Region 2 Forward: 5’-TTAGTTGAGGATCAGATGTGTCA-3’ Reverse: 5’- 
TCAGTGAGCAGAAACTAAGGACA-3’.  The primers were tailored to incorporate a 
Kpn I site and an Xho I site at the end of the amplified regions. Fragments were inserted 
in both the forward and reverse orientation into the vector. 
The amplified regions were purified with the Promega Wizard SV Gel and PCR 
CleanUp System (Promega Corporation, Madison, WI, USA ), digested with Xho I and 
Kpn I restriction endonucleases (New England Biolabs, Ipswich, MA, USA ), and 
subcloned into the Kpn I and Xho I sites of firefly luciferase-expressing pGL4 vectors 
(Promega Corporation).  Region 1 was subcloned into the basic pGL4.10 and the minimal 
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promoter pGL4.23 vectors.  Region 2 was subcloned into the minimal promoter pGL4.23 
vector.  All constructs were sequenced to verify nucleotides at variant positions and to 
identify any additional variant nucleotides in the region.  
 
Cell cultures, transfections, and luciferase assays 
Human HepG2 cells were grown in Dulbecco’s modified Eagle medium with 
10% fetal bovine serum, and 1% sodium pyruvate at 37°C and 5% CO2.  Cells were 
seeded at 8 x 104 to 10 x 104 cells per well in a 24-well collagen-coated plate and allowed 
to grow undisturbed for 24 hours prior to transfection.  Transient transfections were 
performed with FuGENE6 (Roche Applied Science, Indianapolis, IN, USA) according to 
the manufacturer’s protocol.  Specifically, 720 ng of the luciferase reporter construct was 
cotransfected with 80 ng of Renilla luciferase (Promega Corporation) to control for 
variation in transfection efficiency.  Each clone and the corresponding empty vector were 
transfected in duplicate.  
After 48 hours, the transfected cells were lysed with 90 ul of 1x lysis buffer for 45 
minutes by gently rocking at room temperature.  Fifteen microliters of cell lysate was 
harvested and luciferase activity was measured with Dual-Luciferase Reporter Assay 
System (Promega Corporation) using a 96-well microplate luminometer.   
 
Statistical analysis 
Relative luciferase activity is reported as luciferase divided by Renilla relative to 
empty vector.  Results are represented at ± standard deviation of the 2 to 7 independent 
clones.  For Region 1, differences between haplotypes in the luciferase assay data were 
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analyzed by ANOVA and a Tukey post hoc pairwise analysis between haplotypes.  For 
Region 2, luciferase assay data were assessed by a two-sided Student’s t-test.  A P < .05 
was considered statistically significant. 
 
Genotyping rs6143660 insertion-deletion variant 
 Eighty-seven random FUSION samples were chosen for genotyping.  Primers 
for amplification were selected using Primer3 software: Forward: 5’-
CTCATCTTTGCACACGAAGG-3’ Reverse: 5’-GAGACCCTGAGTGTGAGGCT-3’.  
The products for chromosomes with and without the deletion were 91 bp and 112 bp, 
respectively.  The products were run on a 3% low melting point agarose gel, and two 
researchers scored genotypes independently. 
 
RESULTS 
Identifying possible functional variants 
To identify the full set of possible functional SNPs in the GALNT2 HDL-C 
association region (chr1:228,360,704-228,375,798) (Figure 5.1B), we used four 
approaches to perform resequencing and evaluate LD compared to the known HDL-C 
associated SNPs (Table 5.1).  First, to identify novel coding or splice site variants, I 
performed targeted resequencing of GALNT2 exon 2 located downstream of the 15 kb 
region of HDL-C associated SNPs.  No sequence variations were found in the exon. By 
using 48 FUSION samples, I had 99% probability of detecting a variant with a minor 
allele frequency >.05.  Second, additional resequencing of the association region was 
performed in 188 individuals.  Eighty percent of the region was successfully resequenced, 
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and successful amplicons are pictured in Figure 5.1B.  Nine SNPs were identified to be in 
moderate LD (r2>.5) with one of the eight original associated SNPs.  Of these nine, one 
had been previously tested for association in the Kathiresan et al. 2009 GWA study and 
had a P of 3.1 x 10-5.  Third, further examination of HapMap (http://www.hapmap.org) 
CEU variants in strong LD (r2 = 1) with one of the eight original associated SNPs 
identified two additional SNPs.  These two SNPs were not analyzed in the Kathiresan et 
al. 2009 GWA study because they failed quality control and were not identified by 
resequencing because they were located in an amplicon that failed.  Finally, using 
preliminary data from the 1000 Genomes Project (May 2009; 
http://browser.1000genomes.org) we identified five SNPs that were in moderate LD 
(r2>.5) with the best SNP reported by Kathiresan et al. 2009, rs4846914.  In total, 24 
SNPs were identified through resequencing and LD analysis to be potential functional 
SNPs [7].  Detailed descriptions of this set are described in Table 5.1.  
 
Selection of regions with potential regulatory function 
Of the 24 SNPs identified in the association region, four SNPs are located in 
genomic regions that are highly suggestive of regulatory function (rs2144300, rs4846913, 
rs17315646, and rs4846914).  These SNPs are located on the furthest upstream side of 
the association region, within 1 kb (976bp) of one another, and overlap many functional 
annotations including that of open chromatin (DNase HS, FAIRE), histone modification 
(H3K4me3), and chromatin immunoprecipitation (ChIP) with regulatory proteins, Sterol 
regulatory element-binding protein-1A and RNA polymerase II, in HepG2 cells (Figure 
5.1B and 5.1C).  These SNPs thus represent the best candidates at this locus. 
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 This 976 bp section was divided based on the functional annotations into two 
regions to test in the luciferase expression reporter assay (Figure 5.1C).  Region 1 is 780 
bp and includes seven variants, five of which are common (minor allele frequency > .05).  
Region two is 565 bp and includes five variants, three of which are common. Fifty base 
pairs of Region 1 was predicted to fall within a possible promoter by Berkeley 
Drosophila Genome Project Eukaryote Promoter Prediction 
(http://www.fruitfly.org/seq_tools/promoter.html).  Therefore, this region was tested in 
both pGL4.10, a promoterless vector, and pGL4.23, a minimal promoter vector.  Three 
and two haplotypes were tested for functional activity in Region 1 and 2, respectively 
(Table 5.2 and 5.3). 
 
Analyzing the 21 nucleotide deletion - rs6143660 
During the resequencing of the reporter constructs, a 21 nucleotide deletion, 
rs6143660, was found to be common.  To further evaluate this variant, we genotyped the 
deletion in 87 individuals with known genotypes at HDL-C-associated variants. We 
found that the MAF was .36 and the r2 with the HDL-C-associated SNP rs4846914 was 
.88.  While we did not directly test the deletion for association with HDL-C levels, the 
correlation of it with the strongest associated SNP suggests that this deletion may also be 
associated with HDL-C levels. 
 
Allele-specific effect of Haplotype 1 on transcriptional activity in Region 1 
 The genomic fragments from Region 1 with alleles specific to the haplotypes 
described in Table 5.2 were inserted into the firefly luciferase expressing pGL4.10 basic 
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promoterless vector or pGL4.23 minimal promoter vector. The activity of the constructs 
was assessed by transiently transfecting HepG2 cells.   
The luciferase activity of Haplotype 1 was 1.6 to 3-fold higher than that of the 
other haplotypes in the basic vector, in both the forward and reverse orientations (P 
overall < .0001, P overall = .0009; Figure 5.2A).  We performed a Tukey post-hoc test to 
access the differences between individual haplotypes; the P values for the forward 
orientation were P < .0001, P < .0001, and P = .0009 for Haplotype 1 to 2, 1 to 3, and 2 
to 3, respectively. For the reverse orientation, the P values were P = .02, P = .0007, and P 
= .2 for Haplotype 1 to 2, 1 to 3, and 2 to 3, respectively.    
In the minimal promoter vector, the luciferase activity of Haplotype 1 was also 
1.8 to 3-fold higher than that of the other haplotypes, in both the forward and reverse 
orientations (P overall < .0001, P = .0001; Figure 5.2B). The P values for the forward 
orientation were P < .0001, P < .0001, and P = .03 for Haplotype 1 to 2, 1 to 3, and 2 to 
3, respectively. For the reverse orientation, the P values were P = .0008, P = .0002, and P 
= .6 for Haplotype 1 to 2, 1 to 3, and 2 to 3, respectively. 
 
No allele-specific effects in Region 2 
The genomic fragments from Region 2 with alleles specific to the haplotypes 
described in Table 5.3 were also tested for luciferase activity in the minimal promoter, 
pGL4.23, vector.  The luciferase activity demonstrated no difference between the two 
haplotypes in either the forward or reverse orientation (P = .06, P = .1; Figure 5.3).   
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DISCUSSION 
HDL-C is a complex trait that can be affected by multiple genetic and 
environmental factors [3].  In the present study, we explored the functional potential of 
some of the alleles that may be underlying the HDL-C association signal at the GALNT2 
locus by investigating the transcriptional effects of two genomic regions.  We show that 
the SNPs in Haplotype 1 of Region 1 consistently cause a significant increase in 
transcription compared to Haplotype 2 and Haplotype 3 in both a minimal promoter 
vector and a basic vector in the forward and reverse orientation.  The results indicate 
increased transcriptional activity of Haplotype 1 containing the 21 bp deletion of 
rs6143660, the T allele of rs2144300, and the A allele of rs4846913.  These alleles have 
been associated with increased HDL-C levels and may be the potential functional variants 
causing Haplotype 1 to have an increase in transcriptional activity.  Haplotype 2 shows a 
significant increase in transcription compared to Haplotype 3 in the forward direction of 
both vectors but does not show an increase in the reverse direction.  These results suggest 
that the A allele of rs1555290, which differentiates Haplotype 2 from Haplotype 3, may 
also be a potentially functional variant with a modest effect.   
This study is the first known attempt to pinpoint the functional variant(s) 
contributing to the HDL-C association at the GALNT2 locus.  Based on these results, one 
or more of the alleles in Region 1 appear to increase transcription of GALNT2 or another 
transcript.  The luciferase activity for Region 1 is consistently higher than the empty 
vector, with relative luciferase activity as high as 48-fold in the minimal promoter vector 
in the forward direction and activity nearly as high in the promoterless vector. The 
luciferase data as well as the open chromatin data suggest that Region 1 may contain an 
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enhancer or promoter. If the potentially functional variants act directly on GALNT2 then 
increased GALNT2 may lead to increased HDL-C.  On the other hand, these variants 
may also or instead increase transcription of an unknown transcript that leads to increased 
HDL-C.  
Our results should be interpreted cautiously in light of a recent abstract by 
Edmondson et al. (Abstract American Society of Human Genetics 2009), which 
contradicts the direction of our results.  Edmondson overexpressed mouse and human 
GALNT2 in mouse hepatocytes, which led to a significant decrease in HDL-C by 
approximately 20% at 28 days.  Additionally, the knockdown endogenous Galnt2 lead to 
a 37% increase in HDL-C.  These results suggest that GALNT2 is the casual gene at this 
locus and that changes in hepatic GALNT2 expression are associated with inverse 
changes in HDL-C levels. 
While there are no established connections between the function of GALNT2 and 
HDL-C levels, the localized association signal suggests GALNT2 may be the most likely 
gene affecting levels of HDL-C.  GALNT2 codes for a widely expressed N-
actetylgalactosaminyltransferase, which is involved in O-linked glycosylation of proteins. 
GALNT2 is located on the trans side of the golgi stack, and is known to transfer N-
acetylgalactosamine to serine or threonine residues [14].  Because O-linked glycosylation 
can regulate protein function, changes in GALNT2 expression may indirectly affect HDL-
C levels through glycosylating and modifying a lipoprotein or receptor involved in 
metabolism.  Potential target candidates may include LCAT, apoCIII, VLDLR, or LDLR 
because these have been reported to be O-glycosylated with N-acetylgalactosamine 
residues [15-18]. 
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 The luciferase assay experimental approach has several limitations. Luciferase 
reporter assays are an artificial in vitro system that may not represent fully all the 
interacting nuances in the human body.  While GALNT2 is expressed in liver tissue [14] 
and liver is very critical to HDL-C metabolism, GALNT2 may not have its functional 
effects on HDL-C within the liver.  Additionally, we are using HepG2 cells as a proxy for 
in vivo liver tissues, and these cells may not contain all of the regulatory proteins 
biologically relevant to human HDL-C metabolism. 
 While Regions 1 and 2 of the association region seem to be the most obvious for a 
predicted regulatory element, they do not contain all possible functional alleles, and we 
may have not identified the full set of possible functional alleles.  Through the large scale 
resequencing and data from the 1000 Genomes Project, we identified 16 other SNPs and 
one deletion.  The likelihood that we have identified the full set of possible functional 
alleles depends on the unknown frequency of the underlying functional variant(s).   
 The functional activity of the variants in Region 1 can be analyzed in future 
experiments.  The variants could be tested in other biological relevant cell lines, such as 
primary liver cells or muscle-derived cell lines.  In addition, the three variants on 
Haplotype 1 in Region 1 could be isolated to determine if a single variant affects 
transcriptional activity.  Because these SNPs are in high linkage disequilibrium, only very 
rare individuals would have the needed haplotypes.; we could perform site-directed 
mutagenesis to separate the alleles. Region 1 might also be tested as smaller sub-regions 
to isolate the SNP effects.   
In addition to the luciferase assays, there are other methods to determine potential 
functional alleles.  One method is an electrophoretic mobility shift assay. This method 
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allows for the study of protein-DNA interactions to identify if one allele differentially 
binds a specific protein or any protein from cell lystates.  The future directions include 
testing other variants in the association signal that are highly associated or that fall within 
in a predicated regulatory region.  We have the potential to test rare variants within 
GALNT2 that are specific to high or low HDL-C individuals and test to see if these 
variants perturb function.  Additionally, it would be helpful to investigate potential 
proteins that may be modified by GALNT2 and identify the pathway that effects HDL-C 
metabolism.  
In summary, we found that constructs containing the 21 bp deletion of rs6143660, 
the T allele of rs2144300, and the A allele of rs4846913 increased transcriptional activity 
compared to the alternative alleles.  Nonetheless, additional research will be required to 
better define the functional significance of these variants and to clarify the mechanism of 
GALNT2 with HDL-C.  Ultimately, by identifying the causative variant(s) at this locus, 
we may aid in the discovery of therapeutic targets for altering HDL-C levels.  
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Table 5.1: Candidate functional SNPs with annotation in the GALNT2 HDL-C 
associated locus.  
SNP Source 
P value for 
HDL-C 
association1 
r2 with an 
original HDL-
C associated 
SNP 
Potential regulatory 
functional annotation  
Tested 
Region 
rs2144300 Original HDL-C associated SNP1 1.03E-07   
HepG2 DNase HS, 
FAIRE, PolII, 
SREBP1A, H3K4me3 
1 
rs17315646 Original HDL-C associated SNP1 7.24E-08   
HepG2 DNase HS, 
H3K4me3 2 
rs4846914 Original HDL-C associated SNP1 3.91E-08   
HepG2 FAIRE, 
H3K4me3 2 
rs10127775 Original HDL-C associated SNP1 6.86E-08     2 
rs2281719 Original HDL-C associated SNP1 1.02E-07       
rs10779835 Original HDL-C associated SNP1 5.25E-08   HepG2 H3K4me3   
rs10489615 Original HDL-C associated SNP1 9.40E-08       
rs1321257 Original HDL-C associated SNP1 8.23E-08       
rs2281721 188 individual re-sequencing2   1     
rs10864727 188 individual re-sequencing2   1     
rs10864728 188 individual re-sequencing2   1     
rs11122456 188 individual re-sequencing2   1     
rs4846921 188 individual re-sequencing2   .989     
rs2281718 188 individual re-sequencing2   .966     
rs4846922 188 individual re-sequencing2   .915 Most conserved mammal 
and vertebrate   
rs609526 188 individual re-sequencing2 3.10E-05 .729     
rs4846923 188 individual re-sequencing2   .616     
rs11122450 HapMap3   1     
rs4846913 HapMap3   1 HepG2 DNase HS, FAIRE, PolII, SREBP1A 1 
rs34996149 1000 Genomes Project4   .9604     
rs11122454 1000 Genomes Project4   .9604     
rs1546954 1000 Genomes Project4   .6079     
rs11122453 1000 Genomes Project4   .6766     
rs10864726 1000 Genomes Project4   .6079     
1.  Definition and P values from Kathiresan et al. 2009 
2.  Linkage disequilbrium (LD) was obtained from K. Gaulton et al. unpublished 
3.  LD determined by HapMap CEU population 
4.  LD with rs4846914 determined by data from May 2009 of 1000 Genomes Project data  
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Table 5.2: Haplotypes tested in Region 1 
 
* Direction of association was based upon these SNPs. 
rs4846913* rs2144300* rs1555290 rs6143660* Association of alleles
Haplotype 1: A T A - Increase HDL-C
Haplotype 2: C C A + Decrease HDL-C
Haplotype 3: C C C + Decrease HDL-C
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Table 5.3: Haplotypes tested in Region 2 
 
rs17315646 rs4846914 rs10127775 Association of alleles
Haplotype 1: C G A Decreases HDL
Haplotype 2: G A T Increases HDL
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Figure 5.1: Evidence for association with HDL-C and potential regulatory regions at 
the GALNT2 locus 
A. Evidence for association with high density lipoprotein cholesterol (HDL-C) at the 
GALNT2 locus. Evidence for association is shown for evaluated single nucleotide 
polymorphisms (SNPs) in 19,794 GWA samples [7]. The top panel depicts the locations 
of genes. 
B.  Zoom (chr1: 228,360,704-228,375,798) on the region of association in intron one 
with experimental and computationally predicted evidence of regulatory regions.  The 
first track indicates single nucleotide polymorphisms (SNP) within the region. The red 
ovals indicate SNPs evaluated for association with P < 1.02 x 10-7 [7].  Predicted regions 
of open chromatin are indicated by DNase hypersensitivity and formaldehyde-assisted 
identification of regulatory elements using the human hepatocellular carcinoma HepG2 
cell line.  Additional potential regulatory predictors include markers of histone 
modification (H3K4me3), chromatin immunoprecipitation (ChIP) with regulatory 
proteins, and conservation regions.  The bottom track indicates the successful amplicons 
of the 188 individual re-sequencing.  
C.  Zoom on Region 1 and Region 2 with experimental and computationally predicted 
evidence of regulatory regions.  
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Figure 5.2: Allelic differences in transcriptional activity between haplotypes of 
Region 1 in the human hepatocellular carcinoma HepG2 cell line.  Relative luciferase 
activity (firefly luciferase/Renilla luciferase) was determined and fold luciferase activity 
is presented as compared to vector without insert.  Error bars indicated ± standard 
deviation of N independent biological replicate clones. A. Luciferase activity was tested 
in the basic, pGL4.10, vector.  B. Luciferase activity was tested in the minimal promoter, 
pGL4.23, vector. 
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Figure 5.3: Allelic differences in transcriptional activity between haplotypes of 
Region 2 in the human hepatocellular carcinoma HepG2 cell line.  Relative luciferase 
activity (firefly luciferase/Renilla luciferase) was determined and fold luciferase activity 
is presented as compared to vector without insert.  Error bars indicated ± standard 
deviation of N independent biological replicate clones. Luciferase activity was tested in 
the minimal promoter, pGL4.23, vector. 
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 CHAPTER VI.  CONCLUSIONS 
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OVERVIEW OF FINDINGS AND SYNTHESIS 
This dissertation identifies variants that are associated with obesity-related traits 
and lipoprotein levels in the Cebu Longitudinal Health and Nutrition Study (CLHNS), a 
cohort of adult women from the Philippines.  One of the loci identified to influence the 
interindividual variation of high density lipoprotein cholesterol (HDL-C) was further 
investigated to detect the functional variant(s) that are contributing to the association.  
Together, these findings represent important contributions to the field of human genetics 
and will serve as building blocks for future studies.  While each chapter of this 
dissertation can be seen as a standalone paper, the analyses and findings fit together to 
form a cohesive picture of genetic risk factors for cardiovascular disease (CVD).  This 
discussion highlights key points from and relationships between each chapter, the 
significance of the research, and explores future endeavors, which may prove beneficial 
in expanding the understanding of complex traits.  
 
Chapter II:  Comparison of ENCODE region SNPs between Cebu Filipino and 
Asian HapMap samples 
Prior to beginning this study, limited genetic data was available on Filipinos.  The 
detailed population study described in Chapter II was motivated by our plan to select 
genetic polymorphisms representing common variation across the genome for future 
CLHNS studies.  We, therefore, set out to assess the effectiveness of using the Hapmap 
data to guide single nucleotide polymorphism (SNP) selection for the Cebu Filipino 
CLHNS samples.  
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 In order to determine whether a large number of unknown variants would be 
identified, we resequenced a portion of each of the ten ENCODE regions [1] revealing 
only one SNP  (minor allele frequency, MAF > .05) unique to the CLHNS sample and 
not present in dbSNP or HapMap suggesting that SNPs ascertained from the ENCODE 
regions are representative of common variation in Cebu Filipinos. From this result, we 
concluded that no further resequencing would be needed for typical candidate gene 
studies of common (MAF > .05) variants.  Nonetheless, in Chapter V, we resequenced 
exon 2 of GALNT2 in order to identify all potential variants that could be contributing to 
the association signal.   
We were also interested in identifying which of four HapMap populations (CEU, 
CHB, JPT, YRI) [2] would be most closely related to the CLHNS.  The identified 
population could be used for imputation to infer genotypes of un-genotyped SNPs in the 
genome wide association (GWA) study conducted in Chapter IV.  Consistent with major 
population migration patterns, mitochondrial DNA, and Y haplotype patterns, CHB, JPT, 
and CHB+JPT HapMap samples were more similar with respect to allele frequency than 
the CEU and YRI samples.  Based on estimates of pairwise r2 and haplotype frequencies 
of the Asian HapMap samples, the CHB and CHB+JPT panels were used as an efficient 
proxy when choosing haplotype tagging SNPs for CLHNS samples.  Despite Spanish 
presence in the Philippines from the late 16th century to late 19th century, these analyses 
did not detect a significant genetic contribution from the Spanish in the individuals 
examined from Cebu.  The individuals were most similar to the other Asian samples. 
 Because the ENCODE regions represent a range of measures of linkage 
disequilibrium (LD), gene density, and haplotype blocks, the results gleaned from these 
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ten regions may apply, on average, across the genome.  These data are consistent with the 
likelihood that Filipinos from Cebu would not show dramatically different LD compared 
to individuals from China and Japan, suggesting that SNP selection based on CHB and 
JPT HapMap samples is satisfactory.  These findings were useful for the design and 
analysis of genetic studies in the Cebu Filipino population, as presented in Chapter IV. 
 
Chapter III:  Association of FTO with obesity-related traits in the Cebu 
Longitudinal Health and Nutrition Survey (CLHNS) cohort 
 Leading up to the work for this chapter, the underlying genetic components of 
obesity-related traits were not well understood, and there was limited evidence to support 
genetic association shared across multiple studies, populations, and environmental 
contexts.  During this time GWA studies were just beginning, and most of the prior focus 
was on candidate gene studies.  As of 2005, the Human Obesity Gene Map reported 426 
statistically significant associations between obesity-related phenotypes and a DNA 
variant in 127 candidate genes.  Of these genes, 22 were supported by positive replication 
in at least five studies [3].  However, additional reports existed for these loci that were 
inconsistent with preliminary data.  Using the well-characterized CLHNS samples from 
an understudied population provided us with a unique data set to analyze association of 
variants with previous evidence of association with an obesity-related quantitative trait in 
other populations.  The longitudinal anthropometry, diet, and physical activity measures 
provided an outstanding resource to analyze cross-sectional endpoint and longitudinal 
traits and test for interaction effects between SNPs and diet and physical activity. 
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We selected and genotyped 19 single nucleotide polymorphisms in ten genes 
(ADRB2, ADRB3, FTO, GNB3, INSIG2, LEPR, PPARG, TNF, UCP2, and UCP3) that 
had the strongest prior evidence (at the time) of being associated with an obesity-related 
quantitative trait in other populations.  Two of the variants were chosen based on GWA 
studies: the FTO variant rs9939609 and the INSIG2 variant rs7566605.  The other 
variants were identified from candidate gene association studies. 
Of the SNPs tested, only the A allele of FTO variant rs9939609 showed 
significant association in the same direction as seen in other previously reported 
populations. We observed evidence of association with body mass index (BMI), waist 
circumference (measurement of central adiposity), and weight, but not with skinfold 
thicknesses (measurements of subcutaneous adiposity).  These data suggest that variants 
in FTO influence central adiposity to a greater extent than subcutaneous fat. We also 
observed evidence for association with longitudinal BMI, which reflects a relatively 
constant genotype effect over 22 years and strengthens the evidence that this locus 
influences BMI in this population.  We observed an effect even with baseline BMI when 
the women were young and had with smaller BMIs, consistent with an effect over a wide 
age range, which is further supported by previous reports of an FTO effect in children 
[4,5].  There was no evidence for interaction between genotype and either the 2005 
dietary intake (total calories, estimated percent diet from fat, and estimated percent diet 
from carbohydrates) or physical activity measures. This study replicates this evidence in 
a Filipino population suggesting FTO may be important in many genetic backgrounds. 
Additionally, we observed evidence of association with the Trp64 allele of rs4994 
in ADRB3 with increased weight, percent fat mass, arm fat area (AFA), arm muscle area 
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(AMA), and longitudinal BMI, but not with baseline BMI.  However, the direction of 
effect was not consistent with the majority of previous reports suggesting that these 
results should be interpreted with caution.  
There have been many GWA studies published subsequent to this paper that have 
examined obesity-related traits [6-14], and to date, of the 19 tested variants, SNPs in FTO 
have the most consistent and strongest evidence for association with obesity-related 
traits; the variant rs9939609 within FTO has been identified to be associated with 
obesity-related traits in these GWA studies at a genome wide significance threshold (P < 
10-8).  Variants within FTO have evidence of association with many measures of obesity 
in both adults and children and across diverse populations.  One of the reasons for the 
consistent association may be that variants in FTO have one of the strongest effect-sizes 
observed for obesity-related traits.  The common associated variants in intron 1 of FTO 
have an effect of ~3 kilograms for the homozygotes of the risk allele compared to the 
homozygotes of the non-risk allele.   
FTO encodes a 2-oxoglutarate–dependent nucleic acid demethylase [15] and may 
play a role in DNA or RNA repair [16].  FTO is expressed in several tissues including 
adipose, pancreatic islets, skeletal muscle, and hypothalamus suggesting a role in 
regulation of appetite [4,5,15,17].  Recently a study found that Fto-deficient mice have 
growth retardation and reduced adipose and lean body mass caused by increased energy 
expenditure.  This study suggests FTO may play a role in energy homeostatis by 
regulating energy expenditure [18].  However, the exact variant(s) within FTO as well as 
the exact pathway through which FTO is influencing obesity have yet to be identified. 
This uncertainty is true for many loci identified to be associated with obesity-related 
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traits and lipoproteins.  I have attempted to identify which variant(s) is involved within 
the HDL-C association signal in Chapter V when investigating variants within GALNT2 
that are associated with HDL-C levels.  
 The inability of our study and recent GWA studies to corroborate associations of 
the other 18 SNPs identified in previous genetic studies of obesity-related traits 
demonstrates the difficultly of identifying genes using a candidate approach and suggests 
that there may be variable effects across populations.  While variants in the genes from 
candidate gene studies have not reached the stringent GWA threshold of 5 x 10-8 in recent 
GWA studies, these genes may have less significant associations within these studies and 
may still be contributing to obesity-related traits.  As more consortiums are formed and 
GWA studies become larger, these genes may be identified. However, it is notable that 
some genes involved in lipoprotein levels (Chapter IV) were successfully identified in 
candidate gene studies and have consistent evidence of association in recent lipid GWA 
studies.  These genes include: APOB, PCSK9, ABCA1, ANGPTL4, HMGCR, LDLR, 
APOA, CETP, LIPC, LIPG, LPL, GCKR, and APOE [19]. These genes and many others 
were examined for association in Chapter IV. 
The differing association patterns of variants in INSIG2 between studies illustrate 
that SNPs may have variable effects in different populations.  The initial association was 
identified in a GWA study and has been replicated [20-24] in some but not all cohorts 
[25-37].  Recently, I was involved in a GWA study of obesity-related traits in the 
CLHNS lead by D.C. Croteau-Chonka [38].  This study has replicated several, but not all, 
of the findings from current GWA studies for both BMI and weight with MC4R and 
FTO; and for BMI with BDNF.  The differing evidence of associations between 
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populations may be a result of ascertainment or study design, population substructure, 
genotype call rates, and the degree of LD between the variant being tested and the true 
causative variant.  Subsequently, there may be heterogeneity between populations, due to 
underlying and unknown genetic or environmental factors, that can account for the 
differences in associations. 
 
Chapter IV:  Genome-wide association study of lipoprotein cholesterol and 
triglycerides in the Cebu Longitudinal Health and Nutrition Survey (CLHNS) 
cohort 
 The goal of this study was to utilize the CLHNS to capture additional genetic 
diversity and identify important variants that are involved in lipoprotein metabolism that 
might not have been identified in previous studies.  Prior to this research, the majority of 
studies identifying genes for complex diseases were dominated by samples from 
European populations.  However, in order to have a greater understanding of the 
interindividual variation of disease, genetic studies need to include populations with a 
wide range of geographic origins, environmental conditions, and disease burden as it is 
not yet possible to make generalizations about associations of markers across 
populations. 
 Although a targeted effort was made in Chapter II to address the genetic 
structure among the CLHNS women, the GWA study described in this chapter allowed 
for a more thorough analysis of all the samples to identify population admixture and 
unknown relatedness.  Using a set of independent SNPs (r2 < .005), we constructed 
principal components to be included as covariates in the association analyses to account 
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for genetic ancestry differences among study subjects.  Additionally, we determined the 
genomic control values from association scans to examine systematic p-value inflation 
due to cryptic relatedness between samples.  A genomic control value of 1 was 
determined for HDL-C, low density lipoprotein cholesterol (LDL-C), triglycerides, and 
total cholesterol, suggesting good control of the overall family-wise type I error rate.  
Finally, based on identity-by-descent (IBD) and identity-by-state (IBS) estimates, we 
excluded 81 samples that were likely first-degree relatives with another individual in our 
sample.   
 We employed the knowledge gleaned from Chapter II to decide how to conduct 
genotype imputation, an analytic approach that is based on more comprehensively 
genotyped Hapmap data and LD patterns.  Imputation allowed us to evaluate the evidence 
of association at SNPs that were not directly genotyped.  Our data suggested that the use 
of the CHB+JPT as a reference population was appropriate.  Additionally, an evaluation 
had been done to determine “optimal” mixtures of HapMap panels to maximize 
imputation accuracy [39].  Huang et al. recommends using a combination of two or more 
HapMap panels for most populations.  An independent analysis done by Yun Li (data not 
shown) retrospectively on our GWA imputation concluded that using the CEU population 
along with the CHB+JPT population from HapMap gave better imputation results than 
just CHB+JPT alone.  The increase in sample size allowed for a better representation of 
the CLHNS haplotypes across the genome. 
 Our study observed evidence of association with many well-known loci 
implicated in lipid metabolism in previous GWA studies: MMAB/MVK, LIPC (two 
association signals), and CETP (two association signals) with HDL-C; APOA1-APOC3-
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APOA4-APOC2, ANGPTL3/DOCK7, GCKR, LPL, TRIB1, and LIPC with triglycerides; 
and APOE, HMGCR and HNF1A with LDL-C.  As stated above, many of these genes 
were initially identified in candidate gene studies and have shown evidence of association 
across many populations.  Many of these SNPs show an association with more than one 
trait, consistent with the correlations between traits.  Together, all of the previously 
reported SNPs for each trait explain 4.2%, 5.5%, 1%, and .5% of the variation for HDL–
C, triglycerides, LDL-C, and total cholesterol, respectively, leaving most of the 
heritability to be explained.  One possibility is that other genes are playing a role in the 
CLHNS population that have not previously been identified in GWA studies, each loci 
has immeasurable contribution. 
We observed two loci with suggestive evidence of association (P < 10-6) at genes 
that have implications in lipid metabolism: Tankyrase (TNKS) and Collectin-12 
(COLEC12).  Each of these loci account for 1% of the variation in the CLHNS.  TNKS-
deficient mice exhibit increase in energy expenditure, fatty-acid oxidation, and insulin-
stimulated glucose utilization.  In these mice, adiposity is substantially decreased even 
with excessive food intake [40].  COLEC12 mediates the recognition, internalization and 
degradation of oxidatively modified LDL-C by vascular endothelial cells [41].  Both of 
these loci are unique to our study and have not been identified in other GWA studies.  
Because of their biological likelihood, these genes should be studied in additional 
samples for replication in both populations of European and Asian descent. 
 Furthermore, we tested whether genotype associations with lipoprotein levels are 
mediated by BMI.  Obesity is largely responsible for antherogenic dyslipidemia - 
characterized by low levels of HDL-C, increased triglycerides, and increased LDL-C 
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[42].  However, adjusting for BMI did not considerably attenuate or increase the evidence 
of association with most variants, suggesting the changes in lipoprotein levels due to 
these variants and obesity are independent.  However, for the locus ANGPTL3-DOCK7 
with triglycerides we observed a change in P value from .04 with a ß of .038 ±.018 to 
.006 with a ß of .048 ± .017 after adjusting for BMI.  However, this change in P value 
may be the result of stochastic variation.  While ANGPTL3 or DOCK7 are unlikely 
functional candidates, this locus may also be negatively confounded by BMI.  However, 
this locus has not been identified in other genetic studies of obesity-related traits.  
Due to the many challenges in understanding the joint effect of genes and 
environment, we did not analyze these interactions within this study.  There are unlimited 
possible exposures that may be relevant to disease, each of which are difficult to measure 
in detailed repeatable fashion.  These environmental contributions can reduce the power 
to detect a signal and make it hard to distinguish between real heterogeneity and failure to 
replicate.  Additionally, when performing gene by environment interactions, one must 
assume that the environmental variable has no genetic component; however, dietary 
preference and inclination for physical activity may have a significant genetic component 
thus skewing the results. A targeted approach examining genes that have been implicated 
to have a biological significance or are in known pathways that may influence diet or 
physical activity may be a more productive method of performing gene by diet 
interactions.  Future studies in other populations should aim to include environmental 
data to allow for better characterization of the populations. 
 This study explored variants associated with lipoprotein levels; despite the 
success of identifying susceptibility loci there is still much to be learned about each of the 
136 
loci implicated.  In many cases, it is unclear which gene(s) are being affected by the 
associated variants (example MMAB/MVK locus).  In addition, we do not know the role 
of many associated genes in disease biology due to their unknown function or un-linked 
pathway to lipoprotein biology (example GALNT2 Chapter V). 
 
Chapter V:  Transcriptional activity of SNPS at the GALNT2 locus associated with 
human high-density lipoprotein cholesterol levels.  
The main goal of this study was to identify the functional SNP(s) that accounts for 
the HDL-C association signal at the GALNT2 locus.  While the functional SNPs at most 
of the loci associated with lipoprotein levels have yet to be identified, the GALNT2 locus 
was of particular interest because of its relatively localized association signal in intron 
one of GALNT2 (~ 15 kb), the small number of variants within that signal, and the limited 
number of genes located near the signal.  SNPs within GALNT2 have strong evidence of 
association with HDL-C and triglycerides in several GWA studies [19,43].  However, 
there is no evidence of association in the CLHNS population.  Although this locus was 
chosen independently of the lipoprotein association study in Chapter IV, the methods 
utilized in this study can be used to investigate the functional SNPs within other 
associated loci. 
In order to identify the functional variant, we first needed to ensure that we had 
the most inclusive set of SNPs within the association signal.  Performing resequencing of 
exon 2 and dense resequencing of the association region and exons allowed us to identify 
most of the common variants in this region.  However, some of the amplicons for the 
dense resequencing failed, thus, we were limited to ~80% coverage.  Unfortunately, the 
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failed regions were within some of the most interesting predicted functionally important 
regions.  We further supplemented the resequencing results with data from the HapMap 
and the 1000 genomes project (http://browser.1000genomes.org), which at the time of 
analysis had thoroughly resequenced ~45 individuals.  We are confident that we have 
identified most of the common variants at this locus.  However, we will be able to better 
access the entire common genetic variation when more data becomes available from the 
1000 genomes project. 
We used computational and experimental data of open chromatin and histone 
modifications [44,45] in the human hepatocellular carcinoma cell line (HepG2) to 
identify regions that are highly suggestive of regulatory function to prioritize SNPs for 
testing.  These methods have evolved over the last two years to include large genome 
wide scale analyses of multiple tissue types.  We identified two sets of SNPs representing 
the best a priori regulatory candidates at this locus.  We tested haplotypes in two distinct 
genomic regions (Region 1: 780 bp, Region 2: 565 bp) for ability to drive or enhance 
luciferase transcription in HepG2 cells. 
We show that the SNPs in Haplotype 1 containing alleles associated with 
increased HDL-C levels, the 21 bp deletion of rs6143660, the T allele of rs2144300, and 
the A allele of rs4846913 of Region 1 consistently cause a significant increase in 
transcription compared to Haplotype 2 and Haplotype 3 in both a minimal promoter 
vector and a basic vector in the forward and reverse orientation.  These exciting findings 
suggest that one or all three of these variants are strong functional drivers in this region.  
Haplotype 2 of Region 1 with the A allele of rs1555290 shows an increase in 
transcription compared to Haplotype 3 that contains the C allele of rs1555290 in the 
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forward direction of both vectors, but does not show an increase in the reverse direction 
suggesting that this SNP may have a modest effect.  However, the alleles that 
differentiate Haplotype 1 are consistent in both orientations and in both vectors and they 
are strongly associated with HDL-C levels.  rs1555290 has an r2 of .22 with the index 
association SNP (rs4846914).  Additionally rs1555290 was not specifically tested for 
association but is in r2 of .88 with a SNP that was tested, rs2296065, which has a P value 
of 7.1 x 10-6 [46]. In unpublished data from Teslovich et al. (Abstract American Society 
of Human Genetics 2009) of a meta-analysis of 100,000 individuals, rs2296065 is no 
longer among the most significantly associated SNPs and is sifted out in the “noise”. 
These reasons provide strong support that one of these three variants are likely the 
functional variants in the GALNT2 association signal and that rs1555290 may only be 
moderately contributing if at all. We did not observe allele-specific effects of 
transcription for Region 2 suggesting the variants contained in this region do not have a 
role in regulation.  The luciferase data as well as the open chromatin data suggest that 
Region 1 may contain an enhancer or promoter. 
Functional experimental approaches are very problematic in that the causal alleles 
that are being identified in the association signals are likely to have very subtle and 
potentially immeasurable molecular and cellular effects.  Within the human body, these 
alleles may have long-term effects that cannot be identified in artificial settings.  
Additionally, the effects shown in this chapter do not by themselves prove a causal role in 
increased HDL-C.  However, we can speculate that one or all four alleles may play a role 
in regulating transcription. 
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Notably data from Edmondson et al. (Abstract American Society of Human 
Genetics 2009), contradicts the direction of our results.  Edmondson overexpressed 
mouse and human GALNT2 in mouse hepatocytes, which led to a significant decrease in 
HDL-C by approximately 20% at 28 days.  Additionally the knockdown endogenous 
Galnt2 lead to a 37% increase in HDL-C.  These results suggest that GALNT2 is the 
casual gene at this locus and that changes in hepatic GALNT2 expression are associated 
with inverse changes in HDL-C levels.  One hypothesis that could explain this 
inconsistency is that the variants identified in Region 1 are acting in some way to down 
regulate expression of GALNT2.  This possibility could occur if the variants were acting 
on a non-coding RNA that in turn regulated GALNT2 transcription or were competing for 
regulatory proteins with the promoter of GALNT2 causing a decrease in transcription.  As 
we move into the future we may be able to elucidate these irregularities in functional data 
and pinpoint the exact variant(s) that is responsible for the association signal. 
 
SIGNIFICANCE AND FUTURE DIRECTIONS 
These studies presented in this dissertation show how the field of human genetics 
has evolved over the past five years.  Predictably it will continue to evolve; the 
appearance of methods that allow for increased genetic coverage and the accompanying 
data will allow for more detailed exploration, but also present new challenges for analysis 
and interpretation. 
 
Public health significance and personalized medicine 
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Identifying genetic variants that influence susceptibility to risk factors of CVD 
such as obesity-related traits and lipoproteins and understanding how these genes interact 
with modifiable environmental factors has important public health significance. Such 
information can produce additional targeting criteria for disease intervention and 
prevention. 
CVD is an increasing public health burden.  By 2030, an estimated 23.6 million 
people worldwide will die from CVDs, with the largest increase in the number of deaths 
occurring in the South-East Asia Region.  Increasingly, low to middle income countries 
are becoming disproportionally affected by CVDs with ~80% of all CVD deaths taking 
place in these countries.  CVDs are a multidimensional problem caused by a complex 
relationship of environmental, social, economic, and behavioral factors, acting on a 
background of genetic susceptibility.  In order to make strides in reducing disease, we 
must focus on a wide range of research including genetic, molecular, environmental, 
clinical, and epidemiologic studies. 
Ultimately, researchers should seek to translate the results of GWA studies to 
predict an individual’s risks of disease based upon his or her genetic and environmental 
information.  Doctors have long focused on modifiable environmental factors such as 
diet, exercise, and smoking, but the use of genetic information to guide medical decisions 
is on the horizon.  Promises of personalized medicine have been touted over the last few 
years; however, we must first fully understand the biological mechanisms of a disease 
before the reality of this can occur. 
  
Future directions 
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We are now in a new era of human genetics.  We are moving away from 
traditional linkage and candidate gene studies; we are in the prime of GWA studies and 
are progressing towards re-sequencing to identify variants associated with disease. 
The goal of GWA studies is to identify novel loci across the genome that are 
associated with disease.  In the past few years, these studies have identified hundreds of 
variants associated with quantitative traits and common complex disease.  Many new 
genes are now implicated which were not previously known to be involved in disease 
such as GALNT2 leading researchers to learn more about the pathophysiology of disease.  
There is still much work to be done in clarifying the role of these genes where the 
function is not yet known.  
Currently, many population studies are focusing on samples with European 
descent.  As observed in Chapter III and Chapter IV, certain genes identified in the 
European populations are replicated in the CLHNS samples.  However, not all of the 
results from studies in European populations can be generalized to global populations.  
Non-European populations, specifically those of African and Asian ancestry, have 
different genetic structures, disease incidence, and cultural and environmental 
characteristics and must be independently studied in order to be fully understood.  Non-
European populations may be useful in identifying variants that may be important in 
other populations because of ancestry-related differences present in the allele frequencies 
and the pattern of LD [47,48].   
The field of human genetics is progressing towards using larger and larger studies 
such as a meta-analysis, which can examine multiple data sets and overcome the 
limitations of power that can compromise single studies.  An example of a large meta-
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analysis is the Global Lipids Genetics Consortium which includes >100,000 individuals 
of European ancestry  (Teslovich et al., Abstract American Society of Human Genetics 
2009).  It is valuable to consider including a wider range of ethnic groups to support the 
discovery of additional susceptibility variants.  Additionally, we must concentrate on 
creating studies that include specific definitions of traits and environment to best 
eliminate heterogeneity that may cloud the results.   Many of the loci identified and that 
will be identified in GWA studies will only explain a small proportion of the individual 
differences in disease predisposition underscoring the complexity of these traits  
One reason for the relatively limited proportion of phenotypic variation ascribed 
is because current GWA studies have only explored part of the genome variation 
represented by common SNPs.  This method does not comprehensively evaluate 
structural variants such as copy number polymorphisms and rare alleles.   Soon 
technological and analytical advances will allow us to more thoroughly analyze these 
variations.  These types of genetic variation can be identified through deep resequencing; 
the identification of these variants is likely to increase the heritability that can be 
explained as we potentially identify more than one independent causal variant at a locus.   
However, even after we scour all the variation in the genome the entirety of the 
genetic variants that contribute to the interindividual variation of a disease or a trait will 
probably never be identified.  There are almost certainly hundreds or thousands of 
variants within each of us that may be modulated by environment and interactions with 
other variants that contribute minutely to disease.  These variants will be harder and 
harder to identify as human geneticists classify the majority of variants with the strongest 
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genetic effects and begin probing to variants that may affect fewer individuals and have a 
minor effect. 
In order to understand the true contribution of a locus we must progress towards a 
biological understanding of its mechanisms.  The main output of the current research is 
association signals, which can rarely pinpoint a causal variant(s) or even the causal 
gene(s).  This is the next roadblock to translating research to application.  What we will 
glean from these experimental advancements will drive new treatments, biomarkers, and 
prevention. 
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